Non-ATP / catalytic site p38 mitogen-activated protein kinase inhibitors
Selective p38α MAPK inhibitors address the limitations of current p38 inhibitors by binding to the ED substrate docking site, effectively reducing inflammation and lung injury while maintaining counterregulatory functions, applicable for treating a range of diseases.
Patent Information
- Application Number
- JP2021532311
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-07
- Filing Date
- 2019-12-06
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2039-12-06
AI Technical Summary
Current p38 catalytic inhibitors have low efficacy and non-selective inhibition of p38α MAPK, leading to toxicity and loss of counterregulatory responses, necessitating the development of selective p38α MAPK inhibitors to treat inflammatory and neoplastic diseases.
Development of compounds that selectively inhibit p38α MAPK by binding to its ED substrate docking site, maintaining important counterregulatory functions and reducing toxicity.
The compounds effectively inhibit p38α MAPK, reducing inflammation and lung injury while preserving essential cellular functions, offering therapeutic benefits for various diseases including cancer and inflammatory conditions.
Smart Images

Figure 0007594787000099 
Figure 0007594787000100 
Figure 0007594787000101
Abstract
Description
[Technical field]
[0001] The present invention relates generally to compounds that are inhibitors of the p38 mitogen-activated protein kinase (MAPK) protein, and more specifically, but not exclusively, to compounds that inhibit the p38α MAPK protein by binding to a pocket near the ED substrate docking site of p38α MAPK, and methods of using such compounds as treatments for disease. [Background technology]
[0002] p38 mitogen-activated protein kinase (MAPK) contributes to the pathogenesis of many diseases, but currently available p38 catalytic inhibitors (e.g., SB203580) are less effective and cause toxicity, likely due to loss of activity against non-inflammatory p38 isoforms (e.g., p38β) and p38α-dependent counterregulatory responses (e.g., MSK1 / 2).Therefore, there is a need in the art for new therapeutic agents and therapies that address the selective inhibition of p38α MAPK and selectively block specific p38α MAPK functions to maintain important counterregulatory and homeostatic functions, with applications for the treatment of inflammatory and neoplastic diseases. Summary of the Invention
[0003] The present disclosure provides a compound of formula A, or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof: [ka] In formula A, Ar and Ar 1is independently selected from monocyclic or polycyclic optionally substituted cycloalkyl, monocyclic or polycyclic optionally substituted heterocycloalkyl, monocyclic or polycyclic optionally substituted aryl, monocyclic or polycyclic optionally substituted arylalkyl, monocyclic or polycyclic optionally substituted heteroaryl, and monocyclic or polycyclic optionally substituted heteroarylalkyl; R 1 and R 2 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; R 1 and R 2 can be optionally linked to form a carbocyclic or heterocyclic ring; L 1 and L 2 are independently a bond, -NR a -, -S-, -S(O)-, -S(O)2-, -O-, -CR a 2-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(O)NR a -, -NR a C(O)-, -C(O)NR a SO2-, -SO2NR a C(O)-, -OC(O)O-, -OC(O)S-, -SC(O)O-, -OC(O)NR a -, -NR a C(O)O-, -S(O) t N(R a )-(t is 1 or 2), -N(R a )S(O) t-(t is 1 or 2), a linker comprising one or more of disubstituted alkyl, disubstituted heteroalkyl, disubstituted alkenyl, disubstituted alkynyl, disubstituted cycloalkyl, disubstituted heterocycloalkyl, disubstituted aryl, disubstituted arylalkyl, disubstituted heteroaryl, and disubstituted heteroarylalkyl, any optional substituent being independently selected at each occurrence from optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -SC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)SR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, -N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (t is 1 or 2), and PO3 (Ra )2, and R a is independently selected at each occurrence from hydrogen, optionally substituted alkyl, optionally substituted fluoroalkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl. In some embodiments, the optional substituents are independently selected from R 3 , R 4 , R 5 , and R 6 are selected from, independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 Any two of may be optionally linked to form a carbocycle or a heterocycle. 1 is an optionally substituted aryl ring or an optionally substituted heteroaryl ring. In some embodiments, Ar is a monocyclic or polycyclic optionally substituted aryl, a monocyclic or polycyclic optionally substituted arylalkyl, a monocyclic or polycyclic optionally substituted heteroaryl, or a monocyclic or polycyclic optionally substituted heteroarylalkyl. In some embodiments, Ar is a 5- or 6-membered optionally substituted aryl, or a 5- or 6-membered optionally substituted heteroaryl, and L 1 and L 2is linked to Ar in a 1,2, 1,3, or 1,4 substitution pattern. In some embodiments, Ar is a 1,2-, 1,3-, or 1,4-disubstituted phenyl, pyridine, pyrimidine, pyrazine, or triazine. In some embodiments, Ar is a 1,2-, or 1,3-disubstituted furan, thiophene, pyrrole, thiazole, imidazole, oxazole, triazole, or pyrazole. In some embodiments, Ar is a 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, or 1,8-disubstituted naphthalene, quinoline, isoquinoline, or quinazoline. In some embodiments, Ar is a 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, or 1,7-disubstituted indole or imidazole. In some embodiments, L 1 is a linker selected from -CH2-, -C(CH3)2-, and -C(CH2CH2)-; L 2 is a linker selected from -NHCH2-, -CH2NH-, -NHCO-, -CONH-, -SO2NH-, and -NHSO2-; 1 R 2 teeth, [ka] Selected from R 7 is hydrogen or optionally substituted alkyl; Ar 2 is a heterocycle.
[0004] In one aspect, the disclosure relates to a compound of formula I, or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, [ka]
[0005] In formula I, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; 1 and R 2 can be optionally linked to form a carbocyclic or heterocyclic ring; L 1 is a linker selected from -CH2-, -C(CH3)2-, and -C(CH2CH2)-; L 2 is a linker selected from -NHCH2-, -CH2NH-, -NHCO-, -CONH-, -SO2NH-, and -NHSO2-; Ar 1 is an optionally substituted aryl ring or an optionally substituted heteroaryl ring. In some embodiments, -NR 1 R 2 The group is selected from [ka] In the formula, R 7 is hydrogen or optionally substituted alkyl; Ar 2 In some embodiments, the -NR of formula I is 1 R 2 The group is selected from the following: [ka] In some embodiments, L 1 is -CH-. In some embodiments, R 3 , R 4 , R 5 , and R 6 is hydrogen. In some embodiments, L 2 is selected from -NHCH2-, -NHCO-, and -NHSO2-. 1 is selected from: [ka] In the formula, R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 each independently represents hydrogen, halogen, -NR 1 R 2 , alkoxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 Any two vicinal rings of Ar can be optionally linked to form a carbocyclic or heterocyclic ring. 1 is selected from: [ka]
[0006] In another aspect, the present disclosure relates to a compound of formula II, which is any of the compounds of formulas 1001-1180 disclosed in Table 1. [ka]
[0007] In another aspect, the disclosure relates to compounds of any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), and 1087 (SF-7-044). [Table 1-1] [Table 1-2]
[0008] In another aspect, the present disclosure relates to a compound of any of formulas A, I, II, and 1001-1180, which is a p38α MAPK inhibitor. In another aspect, the present disclosure relates to a compound of any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), which is a p38α MAPK inhibitor. In some embodiments, the p38α MAPK inhibitor is a selective inhibitor of p38α MAPK.
[0009] In another aspect, the disclosure relates to a p38α MAPK inhibitor of any of Formula A, Formula I, Formula II, and Formulas 1001-1180, wherein the p38α MAPK inhibitor is capable of binding to a pocket near the ED substrate docking site of p38α MAPK and is defined by at least residues R49, H107, L108, and K165 of p38α MAPK. In some embodiments, the binding pocket is defined by residues R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK. In some embodiments, the p38α MAPK inhibitor is a selective inhibitor of p38α MAPK.
[0010] In another aspect, the present disclosure relates to a p38α MAPK inhibitor of any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), wherein the p38α MAPK inhibitor is capable of binding to a pocket near the ED substrate docking site of p38α MAPK and defined by at least residues R49, H107, L108, and K165 of p38α MAPK. In some embodiments, the binding pocket is defined by residues R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK. In some embodiments, the p38α MAPK inhibitor is a selective inhibitor of p38α MAPK.
[0011] In one aspect, the disclosure relates to a pharmaceutical composition comprising a compound of any of Formula A, Formula I, Formula II, and Formulas 1001-1180, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, and a physiologically compatible carrier medium, wherein the amount of compound in the composition is a therapeutically effective amount for the treatment or prevention of a disease that is alleviated by inhibiting the activity of p38α MAPK. In another aspect, the disclosure relates to a pharmaceutical composition comprising a compound of any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, and a physiologically compatible carrier medium, wherein the amount of compound in the composition is a therapeutically effective amount for the treatment or prevention of a disease alleviated by inhibiting the activity of p38α MAPK. In some embodiments, the disease is cancer or an inflammatory disease. In some embodiments, the disease is selected from the group consisting of rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), and acute lung injury (ALI).In some embodiments, the cancer is acoustic neuroma, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chordoma, choriocarcinoma, colon cancer, colorectal cancer, craniopharyngeal carcinoma, cystadenocarcinoma, embryonal carcinoma, endothelioma, ependymoma, epithelial carcinoma, esophageal carcinoma, Ewing's tumor, fibrosarcoma, gastric cancer, glioblastoma multiforme, glioma, head and neck cancer. , hemangioblastoma, hepatocellular carcinoma, kidney cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, nasal cancer, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma, retinoblastoma, sarcoma , sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, gastric cancer, sweat gland carcinoma, synovium, testicular cancer, small cell lung cancer, pharyngeal cancer, uterine cancer, Wilms' tumor, blood cancer, acute erythroleukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monoblastic leukemia, acute myeloblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute promyelocytic leukemia, acute anaplastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, multiple myeloma, heavy chain disease, Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, polycythemia vera, and Waldenstrom's macroglobulinemia.
[0012] In one aspect, the disclosure relates to a method of treating or preventing a disease that is alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a p38α MAPK inhibitor, or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, wherein the p38α MAPK inhibitor is a compound of any of Formulas A, I, II, and 1001-1180. In another aspect, the disclosure relates to a method of treating or preventing a disease that is alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a p38α MAPK inhibitor, or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, wherein the p38α MAPK inhibitor is a compound of any of Formulas 1001 (SF-6-22 1), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044). In some embodiments, the p38α MAPK inhibitor is administered in a dosage unit form. In some embodiments, the dosage unit comprises a physiologically compatible carrier medium. In some embodiments, the disease is cancer or an inflammatory disease. In some embodiments, the disease is selected from the group consisting of rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), and acute lung injury (ALI).In some embodiments, the cancer is acoustic neuroma, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chordoma, choriocarcinoma, colon cancer, colorectal cancer, craniopharyngeal carcinoma, cystadenocarcinoma, embryonal carcinoma, endothelioma, ependymoma, epithelial carcinoma, esophageal carcinoma, Ewing's tumor, fibrosarcoma, gastric cancer, glioblastoma multiforme, glioma, head and neck cancer. , hemangioblastoma, hepatocellular carcinoma, kidney cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, nasal cancer, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma, retinoblastoma, sarcoma , sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, gastric cancer, sweat gland carcinoma, synovium, testicular cancer, small cell lung cancer, pharyngeal cancer, uterine cancer, Wilms' tumor, blood cancer, acute erythroleukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monoblastic leukemia, acute myeloblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute promyelocytic leukemia, acute anaplastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, multiple myeloma, heavy chain disease, Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, polycythemia vera, and Waldenstrom's macroglobulinemia. In some embodiments, the compound selectively inhibits p38α MAPK. In some embodiments, inhibition of p38α MAPK does not result in loss of p38α-dependent counterregulatory response. In some embodiments, the p38α-dependent counterregulatory response is related to mitogen and stress-activated protein kinase-1 (MSK1) or MSK2. In some embodiments, inhibition of p38α MAPK stabilizes endothelial or epithelial barrier function. In some embodiments, inhibition of p38α MAPK reduces inflammation. In some embodiments, inhibition of p38α MAPK reduces lung injury. In some embodiments, inhibition of p38α MAPK reduces LPS-induced lung injury. In some embodiments, inhibition of p38α MAPK regulates leukocyte trafficking. In some embodiments, inhibition of p38α MAPK regulates cytokine expression.
[0013] In one aspect, the disclosure relates to a method of treating or preventing a disease that is alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of any of Formula A, Formula I, Formula II, and Formulas 1001-1180, or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, and a physiologically compatible carrier medium. In another aspect, the disclosure relates to a method of treating or preventing a disease alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, and a physiologically compatible carrier medium. In some embodiments, the composition is administered in a dosage unit form. In some embodiments, the dosage unit comprises a physiologically compatible carrier medium. In some embodiments, the disease is cancer or an inflammatory disease. In some embodiments, the disease is selected from the group consisting of rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), and acute lung injury (ALI).In some embodiments, the cancer is acoustic neuroma, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chordoma, choriocarcinoma, colon cancer, colorectal cancer, craniopharyngeal carcinoma, cystadenocarcinoma, embryonal carcinoma, endothelioma, ependymoma, epithelial carcinoma, esophageal carcinoma, Ewing's tumor, fibrosarcoma, gastric cancer, glioblastoma multiforme, glioma, head and neck cancer. , hemangioblastoma, hepatocellular carcinoma, kidney cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, nasal cancer, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma, retinoblastoma, sarcoma , sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, gastric cancer, sweat gland carcinoma, synovium, testicular cancer, small cell lung cancer, pharyngeal cancer, uterine cancer, Wilms' tumor, blood cancer, acute erythroleukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monoblastic leukemia, acute myeloblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute promyelocytic leukemia, acute anaplastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, multiple myeloma, heavy chain disease, Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, polycythemia vera, and Waldenstrom's macroglobulinemia. In some embodiments, the compound selectively inhibits p38α MAPK. In some embodiments, inhibition of p38α MAPK does not result in loss of p38α-dependent counterregulatory response. In some embodiments, the p38α-dependent counterregulatory response is related to mitogen and stress-activated protein kinase-1 (MSK1) or MSK2. In some embodiments, inhibition of p38α MAPK stabilizes endothelial or epithelial barrier function. In some embodiments, inhibition of p38α MAPK reduces inflammation. In some embodiments, inhibition of p38α MAPK reduces lung injury. In some embodiments, inhibition of p38α MAPK reduces LPS-induced lung injury. In some embodiments, inhibition of p38α MAPK regulates leukocyte trafficking. In some embodiments, inhibition of p38α MAPK regulates cytokine expression.
[0014] In one aspect, the disclosure relates to a therapeutically effective amount of a p38α MAPK inhibitor, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, for use in the treatment or prevention of a disease alleviated by inhibiting p38α MAPK protein in a patient in need thereof, wherein the p38α MAPK inhibitor is any compound of Formula A, Formula I, Formula II, and Formulas 1001-1180. In another aspect, the disclosure relates to a therapeutically effective amount of a p38α MAPK inhibitor, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, for use in the treatment or prevention of a disease alleviated by inhibiting p38α MAPK protein in a patient in need thereof, wherein the p38α MAPK inhibitor is any of the compounds of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), and 1087 (SF-7-044). In some embodiments, the p38α MAPK inhibitor is administered in a dosage unit form. In some embodiments, the dosage unit comprises a physiologically compatible carrier medium. In some embodiments, the disease is cancer or an inflammatory disease. In some embodiments, the disease is selected from the group consisting of rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), and acute lung injury (ALI).In some embodiments, the cancer is acoustic neuroma, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chordoma, choriocarcinoma, colon cancer, colorectal cancer, craniopharyngeal carcinoma, cystadenocarcinoma, embryonal carcinoma, endothelioma, ependymoma, epithelial carcinoma, esophageal carcinoma, Ewing's tumor, fibrosarcoma, gastric cancer, glioblastoma multiforme, glioma, head and neck cancer. , hemangioblastoma, hepatocellular carcinoma, kidney cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, nasal cancer, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma, retinoblastoma, sarcoma , sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, gastric cancer, sweat gland carcinoma, synovium, testicular cancer, small cell lung cancer, pharyngeal cancer, uterine cancer, Wilms' tumor, blood cancer, acute erythroleukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monoblastic leukemia, acute myeloblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute promyelocytic leukemia, acute anaplastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, multiple myeloma, heavy chain disease, Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, polycythemia vera, and Waldenstrom's macroglobulinemia. In some embodiments, the compound selectively inhibits p38α MAPK. In some embodiments, inhibition of p38α MAPK does not result in loss of p38α-dependent counterregulatory response. In some embodiments, the p38α-dependent counterregulatory response is related to mitogen and stress-activated protein kinase-1 (MSK1) or MSK2. In some embodiments, inhibition of p38α MAPK stabilizes endothelial or epithelial barrier function. In some embodiments, inhibition of p38α MAPK reduces inflammation. In some embodiments, inhibition of p38α MAPK reduces lung injury. In some embodiments, inhibition of p38α MAPK reduces LPS-induced lung injury. In some embodiments, inhibition of p38α MAPK regulates leukocyte trafficking. In some embodiments, inhibition of p38α MAPK regulates cytokine expression. [Brief description of the drawings]
[0015] The foregoing summary, as well as the following detailed description of embodiments of the present invention, will be better understood when read in conjunction with the appended drawings and figures.
[0016] [Figure 1] Figures 1A-1F show the design of substrate-selective p38 inhibitors. Figure 1A shows the structure of p38α showing the CD, ED, DEF, and activation sites. Figure 1B shows a comparison between p38α and β structures. The CD and ED sites are in red and blue, and the CADD target is in yellow. The sequences containing the CADD target on p38α and the corresponding site on p38β differ in only three of ten amino acids (highlighted in yellow). Figure 1C shows the overlap of the CADD target structures in apo (PDB:1p38, green) and dually phosphorylated (PDB:3PY3, yellow) mouse p38α. Figure 1D shows an overview of the CADD screening strategy. Figure 1E shows the DSF screening of compounds added at 10, 25, 50, or 100 μM to recombinant p38α or ERK2, with binding indicated by an increase in melting temperature. Compounds that bind to ERK2 and p38α are highlighted in yellow. Only those that bind to p38α are highlighted in blue. Figure IF shows the chemical structures of UM60, UM101, and SB203580. [Diagram 2]Figures 2A-2D show the biological effects of p38 inhibitors. Figures 2A and 2B show the effect of 10 μM SB203580 (SB), or the indicated concentrations of UM60 or UM101, on HMVECL permeability (Figure 2A) and IL-8-specific neutrophil TEM capacity (Figure 2B). Cells were pretreated with DMSO or compounds for 1 h and then incubated with 10 ng / ml TNFα for 6 h before permeability assay (Figure 2A) or incubated at 39.5 °C for 6 h without additional stimulation before TEM assay (Figure 2b). Mean values ± SE. * indicates p<0.0001 (vs. DMSO), † indicates p<0.0001 (vs. SB), ‡ indicates p<0.005 (vs. 37 °C). Figures 2C and 2D. Male CD1 mice were pretreated with 1 mg SB or 0.1–1 mg UM101 prior to intratracheal (it) instillation of 50 μg LPS and heat exposure. * indicates p<0.05 (vs. DMSO). [Diagram 3]Figures 3A-3K show the biochemical effects of substrate-selective p38 inhibitors. Figures 3A and 3B illustrate heat maps from RNASeq showing the IPA pathway inhibited by SB203580 alone or SB203580 and UM101 (Figure 3A), as well as the IPA pathway inhibited only by UM101 (Figure 3B). Figure 3C shows the biochemical effects of substrate-selective p38 inhibitors on HeLa cells pretreated with 50 μM UM101 or 10 μM SB203580 (SB) for 30 min, followed by treatment with anisomycin for 10-60 min and immunoblotting for phosphorylated MK2, Stat-1 and total p38. Figure 3D shows DSF analysis of UM101 and SB203580 (SB) binding to recombinant p38α and p38β. Mean ± SE of four experiments. *, †, and § indicate p<0.0001 vs. p38α (with DMSO), vs. p38β (with DMSO), and vs. p38β (with SB203580), respectively. P<0.0001 by MANOVA for the difference between UM101 binding to p38α and p38β. Figure 3E shows DSF analysis of UM101 and SB203580 (SB) binding to recombinant wild-type p38α and mutant p38α carrying four mutations in the CADD target pocket. Means ± SE of four experiments. * and † indicate p<0.0001 vs. wild-type (with DMSO) and vs. mutant (with DMSO), respectively. P<0.0001 by MANOVA for the difference between UM101 binding to wild-type and mutant p38α. Figures 3F-K show STD-NMR performed with UM101 and p38α (Figures 3F and 3G), p38β (Figures 3H and 3I), and p38α mutants (Figures 3J and 3K). 1D spectra (Figures 3F, 3H, and 3J) and STD spectra (Figures 3G, 3I, and 3K) from the same samples are shown. Tentative peak assignments are shown in Figure 3F. The inset shows the structure of UM101 with proton labeling. [Figure 4]Preliminary analysis of IL-8 and IL-1β mRNA by qRT-PCR prior to RNASeq. HMVECLs were preincubated with 0.4% DMSO, 10 μM SB203580, or 100 μM UM101 for 1 h, then stimulated with 10 ng / ml TNFα for 4 h, total RNA was harvested, reverse transcribed, and analyzed by qRT-PCR to obtain fold change relative to unstimulated control cells calculated using the delta-delta method with GAPDH as the housekeeping gene. [Diagram 5] Quadrant map of RNASeq analysis. Genes with at least 10 reads in one sample per set and at least a 2-fold increase in TNFα are shown. The major component points in the direction of change in UM101 / SB203580-treated cells relative to DMSO-treated cells. [Figure 6] FragMap of p38α SILCS. The non-polar map (green) shows the putative binding pocket and the location of the ED site is indicated. Maps of hydrogen bond donors (blue) and acceptors (red) are shown. [Figure 7] Figure 1 illustrates compound UM101 overlaid on a FragMap from SILCS shown in wireframe with -1.0 kcal / mol contours for aromatic (purple), aliphatic (green), positively charged (cyan), hydrogen bond acceptor (red) and hydrogen bond donor (blue) functional groups on the p38α backbone, with the side chains of the four residues mutated in our CADD site-disrupting mutant shown. The spatial distribution of the FragMap indicates where each functional group makes a favorable contribution to binding. [Figure 8] We show that UM101 and analogs inhibit thrombin-induced cell permeability. Endothelial cells were pretreated with or without 10 or 15 mM UM101, SF-6-222 (6222), or SF-7-009 (7009). Cell permeability was measured using transepithelial / transendothelial electrical resistance (TEER). [Figure 9]We show that UM101 and analogs inhibit acute lung injury in a mouse model. Mice were pretreated with 1 mg of test compound intraperitoneally (ip) and then treated with 100 mg of LPS intratracheally (it) at 39°C to induce inflammation. Lung injury was assessed by measuring total protein in lung lavage fluid. [Figure 10] Figure 1 shows that UM101 and analogs inhibit acute lung injury in a mouse model. All mice received 50 μg LPS (it) and were kept at 39° C. for 24 hours. All treatments were 1 mg in 0.5 ml DMSO and were administered 6 hours after LPS. Mean ± SM, n=5. *, p=0.03 vs. DMSO#1, †, p=0.16 vs. DMSO#2. Lung injury was assessed by measuring total protein in lung lavage fluid. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications mentioned herein are incorporated by reference in their entirety.
[0018] definition As used herein, the terms "administer," "administration," or "administering" refer to (1) providing, giving, dispensing, and / or prescribing, either by or under the direction of a medical practitioner or his / her authorized representative, in accordance with this disclosure, and / or (2) injecting, ingesting, or consuming into a mammal in accordance with this disclosure.
[0019] The terms "co-administration," "co-administering," "administered in combination with," "administering in combination with," "simultaneous," and "concurrent," as used herein, encompass administration of two or more active pharmaceutical ingredients to a subject such that both active pharmaceutical ingredients and / or their metabolites are present in the subject at the same time. Concurrent administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which two or more active pharmaceutical ingredients are present. Concurrent administration in separate compositions and administration in a composition in which both agents are present are preferred.
[0020] The terms "active pharmaceutical ingredient" and "drug" include the p38α MAPK inhibitors described herein, more specifically, the p38α MAPK inhibitors described by Formula A, Formula I, Formula II, Formulas 1001-1180, particularly Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044). The terms "active pharmaceutical ingredient" and "drug" may also include compounds described herein that bind to p38α MAPK protein, thereby modulating the activity of p38α MAPK protein.
[0021] The term "isostere" refers to a group or molecule whose chemical and / or physical properties are similar to those of another group or molecule. A "bioisostere" is a type of isostere and refers to a group or molecule whose biological properties are similar to those of another group or molecule. For example, in the case of the p38α MAPK inhibitors described herein, the carboxylic acid can be replaced by one of the following bioisosteres in place of the carboxylic acid, including but not limited to alkyl ester (COOR), acylsulfonamide (CONR-SOR), hydroxamic acid (CONR-OH), hydroxamate (CONR-OR), tetrazole, hydroxyisoxazole, isoxazol-3-one, and sulfonamide (SONR), where each R can independently represent hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0022] The term "in vivo" refers to events that take place inside a subject's body.
[0023] The term "in vitro" refers to events that take place outside of a subject's body. In vitro assays include cell-based assays, in which live or dead cells are used, and can also include cell-free assays, in which no intact cells are used.
[0024] The term "effective amount" or "therapeutically effective amount" refers to an amount of a compound or combination of compounds described herein that is sufficient to perform the intended use, including but not limited to disease treatment. Therapeutically effective amounts may vary depending on the intended use (in vitro or in vivo), or the subject and disease state to be treated (e.g., the subject's weight, age, and sex), the severity of the disease state, the method of administration, etc., which can be easily determined by one of ordinary skill in the art. The term also applies to a dose that induces a particular response in target cells (e.g., reduced platelet adhesion and / or cell migration). The particular dose will vary depending on the particular compound selected, the dosing regimen followed, whether the compound is administered in combination with other compounds, the timing of administration, the tissue to which it is administered, and the physical delivery system in which the compound is delivered.
[0025] A "therapeutic benefit," as that term is used herein, encompasses a therapeutic benefit and / or a prophylactic benefit. A prophylactic benefit includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
[0026] As used herein, the terms "treat", "treatment", and / or "treating" may refer to the management of a disease, disorder, or pathological condition, or a symptom thereof, with the intent to cure, ameliorate, stabilize, and / or control the disease, disorder, or pathological condition, or a symptom thereof. More specifically, with respect to the control of a disease, disorder, or pathological condition, "control" may include the absence of condition progression, as assessed by response to the methods listed herein, and such response may be complete (e.g., the disease is in remission) or partial (e.g., any symptoms associated with the condition are reduced or alleviated). As used herein, the terms "prevent", "preventing", and / or "prevention" may refer to reducing the risk of a disease, disorder, or pathological condition occurring.
[0027] As used herein, the terms "modulate" and "modulation" refer to a change in the biological activity of a biological molecule (e.g., a protein, a gene, a peptide, an antibody, etc.), and such a change may relate to an increase in the biological activity of the biological molecule (e.g., an increase in activity, agonism, activation, expression, upregulation, and / or an increase in expression) or a decrease in the biological activity (e.g., a decrease in activity, antagonism, suppression, deactivation, downregulation, and / or a decrease in expression). For example, the compounds described herein may modulate (i.e., inhibit) p38α MAPK protein. In some embodiments, the compounds described herein may selectively modulate (i.e., selectively inhibit) p38α MAPK protein compared to other MAPK or p38 MAPK proteins. In some embodiments, the compounds described herein may selectively modulate (i.e., selectively inhibit) p38α MAPK protein compared to other MAPK or p38 MAPK proteins.
[0028] The terms "QD", "qd", or "qd" mean once a day, once a day, or once daily. The terms "BID", "bid", or "bid" mean twice a day, twice a day, or twice daily. The terms "TID", "tid.", or "tid" mean three times a day, three times a day, or three times daily. The terms "QID", "qid", or "qid" mean four times a day, four times a day, or four times daily.
[0029] The term "pharmaceutically acceptable salts" refers to salts derived from various organic and inorganic counterions known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Preferred inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Preferred organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins. Specific examples include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharma-ceutically acceptable base addition salt is selected from ammonium, potassium, sodium, calcium, and magnesium salts. The term "cocrystal" refers to a molecular complex derived from a number of cocrystal formers known in the art. Unlike salts, cocrystals typically do not involve hydrogen transfer between the cocrystal and the drug, but instead involve intermolecular interactions such as hydrogen bonding, aromatic ring stacking, or dispersion forces between the cocrystal former and the drug in the crystal structure.
[0030] "Pharmaceutically acceptable carrier" or "Pharmaceutically acceptable excipient" or "physiologically compatible" carrier or carrier medium is intended to include any and all solvents, dispersion media, coating agents, antibacterial and antifungal agents, isotonic and absorption delaying agents, and inactive ingredients. The use of such pharmaceutically acceptable carriers or pharmaceutically acceptable excipients for active pharmaceutical ingredients is well known in the art. Except where any conventional pharmaceutically acceptable carrier or pharmaceutically acceptable excipient is incompatible with the active pharmaceutical ingredient, its use in the therapeutic composition of the present invention is contemplated. Additional active pharmaceutical ingredients, such as other drugs, can also be incorporated into the compositions and methods described.
[0031] "Prodrug" refers to a derivative of the compounds described herein, whose pharmacological action results from conversion to an active compound by chemical or metabolic processes in vivo. Prodrugs include compounds in which an amino acid residue, or a polypeptide chain of two or more (e.g., two, three, or four) amino acid residues, is covalently linked via an amide or ester bond to a free amino, hydroxyl, or carboxylic acid group of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044). Amino acid residues include, but are not limited to, the 20 naturally occurring amino acids, generally designated by one-letter or three-letter symbols, but also include, for example, 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, 3-methylhistidine, β-alanine, γ-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine, and methionine sulfone. Additional types of prodrugs are also encompassed. For example, free carboxyl groups can be derivatized as amides or alkyl esters (e.g., methyl esters and acetoxymethyl esters). Prodrug esters as used herein include esters and carbonates formed by reacting one or more hydroxyls of the compounds of the present method with alkyl, alkoxy, or aryl substituted acylating agents using procedures known to those skilled in the art to produce acetates, pivalates, methyl carbonates, benzoates, and the like. As a further example, free hydroxyl groups may be derivatized using groups including, but not limited to, hemisuccinate, phosphate ester, dimethylaminoacetate, and phosphoryloxymethyloxycarbonyl, as reviewed in Advanced Drug Delivery Reviews, 1996, 19, 115.Carbamate prodrugs of hydroxyl and amino groups are also included, as are carbonate prodrugs, sulfonate prodrugs, sulfonate esters, and sulfate esters of hydroxyl groups.Free amines can also be derivatized to amides, sulfonamides, or phosphonamides.All of the prodrug moieties described can incorporate groups including, but not limited to, ether, amine, and carboxylic acid functionalities.In addition, any compound that can be converted in vivo to provide a bioactive agent (e.g., compounds of formulas A, I, II, III, and IV) is a prodrug within the scope of the present invention.Various forms of prodrugs are well known in the art. Comprehensive descriptions of prodrugs and prodrug derivatives can be found in: (a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., (Academic Press, 1996); (b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985); (c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds., (Harwood Academic Publishers, 1991). In general, prodrugs may be designed to improve penetration of the drug across biological membranes in order to obtain improved drug absorption, to extend the duration of action of the drug (slow release of the parent drug from the prodrug, reduced first pass metabolism of the drug), to target drug action (e.g., organ or tumor targeting, lymphocyte targeting), to alter or improve the water solubility of the drug (e.g., iv preparations and eye drops), to improve local drug delivery (e.g., dermal and ocular drug delivery), to improve the chemical / enzymatic stability of the drug or to reduce off-target drug effects, and more generally to improve the therapeutic efficacy of the compounds utilized in the present invention.
[0032] Unless otherwise stated, chemical structures depicted herein are intended to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds in which one or more hydrogen atoms are replaced by deuterium or tritium, or compounds in which one or more carbon atoms are 13 C- or 14 Compounds replaced by C-enriched carbons are within the scope of the present invention.
[0033] When ranges are used herein to describe physical or chemical properties, such as, for example, molecular weight or chemical formula, all combinations and subcombinations of ranges, as well as specific embodiments therein, are intended to be included. The use of the term "about" when referring to a numerical value or numerical range means that the referenced numerical value or numerical range is approximate within experimental variation (or within statistical experimental error), and thus the numerical value or numerical range may vary. The variation is typically 0% to 15%, or 0% to 10%, or 0% to 5% of the stated numerical value or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises", or "having" or "including") includes embodiments thereof, such as, for example, "consist of" or "consist essentially of" the described features, any composition, method, or process embodiment.
[0034] "Alkyl" refers to an alkyl group containing no unsaturation and having 1 to 10 carbon atoms, such as (C 1~10 ) alkyl or C 1~10"alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, having a cyclic alkyl group (alkyl). Whenever it appears herein, a numerical range such as "1-10" refers to each integer within the given range, for example, "1-10 carbon atoms" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 10 carbon atoms, although this definition is also intended to encompass occurrences of the term "alkyl" where no numerical range is specifically specified. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, isobutyl, tertiary butyl, pentyl, isopentyl, neopentyl, hexyl, septyl, octyl, nonyl, and decyl. The alkyl moiety may be attached to the remainder of the molecule by a single bond, such as, for example, methyl (Me), ethyl (Et), n-propyl (Pr), 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), and 3-methylhexyl. Unless otherwise stated in the specification, alkyl groups are independently selected from heteroalkyl, acylsulfonamido, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR. a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NRa )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a 2, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0035] "Alkylaryl" refers to an -(alkyl)aryl radical, where the aryl and alkyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for aryl and alkyl, respectively.
[0036] "Alkylhetaryl" refers to an -(alkyl)hetaryl radical, where the hetaryl and alkyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for aryl and alkyl, respectively.
[0037] "Alkylheterocycloalkyl" refers to an -(alkyl)heterocyclic radical, where the alkyl and heterocycloalkyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for heterocycloalkyl and alkyl, respectively.
[0038] An "alkene" moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon double bond. An "alkyne" moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon triple bond. The alkyl moiety may be branched, straight chain, or cyclic, whether saturated or unsaturated.
[0039] "Alkenyl" refers to an alkyl group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from 2 to 10 carbon atoms (i.e., (C 2~10 ) alkenyl or C 2~10 alkenyl). Each time it appears herein, a numerical range such as "2 to 10" refers to each integer within the given range, for example, "2 to 10 carbon atoms" means that the alkenyl group can consist of 2 carbon atoms, 3 carbon atoms, and so on, up to and including 10 carbon atoms. The alkenyl moiety can be attached to the remainder of the molecule by a single bond, such as, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, and penta-1,4-dienyl. Unless otherwise stated herein, the alkenyl group can be independently selected from the group consisting of alkyl, heteroalkyl, acylsulfonamido, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a, -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0040] "Alkenyl-cycloalkyl" refers to an -(alkenyl)cycloalkyl radical, in which the alkenyl and cycloalkyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for alkenyl and cycloalkyl, respectively.
[0041] "Alkynyl" refers to an alkyl group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, and having from 2 to 10 carbon atoms (i.e., (C 2~10 ) alkynyl or C 2~10"alkynyl" refers to a straight or branched hydrocarbon chain radical group having an alkyl group, alkyl aryl ... a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR aOptionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0042] "Alkynyl-cycloalkyl" refers to an -(alkynyl)cycloalkyl radical, in which the alkynyl and cycloalkyl are as disclosed herein and are optionally substituted by one or more of the substituents described as suitable substituents for alkynyl and cycloalkyl, respectively.
[0043] "Acylsulfonamide" is the group -C(=O)NR a -S(=O)2R a Each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0044] "Carboxaldehyde" refers to the --(C.dbd.O)H radical.
[0045] "Carbonyl" refers to the -C(=O)- group. The carbonyl group is optionally substituted with the following exemplary substituents: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, acylsulfonamido, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -NR a-OR a -, -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a )2, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0046] "Carboxyl" refers to the --(C.dbd.O)OH radical.
[0047] "Cyano" refers to the -CN radical.
[0048] "Cycloalkyl" refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen and may be saturated or partially unsaturated. Cycloalkyl groups contain 3 to 10 ring atoms (i.e., (C 3~10 ) Cycloalkyl or C 3~10Each time it appears herein, a numerical range such as "3 to 10" refers to each integer within the given range, for example, "3 to 10 carbon atoms" means that the cycloalkyl group can consist of up to and including 10 carbon atoms, such as 3 carbon atoms. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl, and the like. Unless otherwise stated herein, cycloalkyl groups are independently selected from the group consisting of alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, acylsulfonamido, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t ORa (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0049] "Cycloalkyl-alkenyl" refers to an -(cycloalkyl)alkenyl radical, in which the cycloalkyl and alkenyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for cycloalkyl and alkenyl, respectively.
[0050] "Cycloalkyl-heterocycloalkyl" refers to a -(cycloalkyl)heterocycloalkyl radical, where cycloalkyl and heterocycloalkyl are as disclosed herein and are optionally substituted by one or more of the substituents described as suitable substituents for cycloalkyl and heterocycloalkyl, respectively.
[0051] "Cycloalkyl-heteroaryl" refers to a -(cycloalkyl)heteroaryl radical, where the cycloalkyl and heteroaryl are as disclosed herein and are optionally substituted by one or more of the substituents described as suitable substituents for cycloalkyl and heteroaryl, respectively.
[0052] The term "alkoxy" refers to an -O-alkyl group containing from 1 to 8 carbon atoms in a straight, branched, or cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, and cyclohexyloxy. "Lower alkoxy" refers to an alkoxy group containing from 1 to 6 carbons.
[0053] The term "substituted alkoxy" refers to an alkoxy in which the alkyl moiety is substituted (i.e., -O-(substituted alkyl)). Unless otherwise stated in the specification, the alkyl portions of the alkoxy group are independently selected from alkyl, heteroalkyl, alkenyl, acylsulfonamido, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a(t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0054] The term "alkoxycarbonyl" refers to a group of the formula (alkoxy)(C=O)- attached through the carbonyl carbon, where the alkoxy group has the indicated number of carbon atoms. Thus, (C 1~6 A "lower alkoxycarbonyl" refers to an alkoxycarbonyl group in which the alkoxy group is a lower alkoxy group.
[0055] The term "substituted alkoxycarbonyl" refers to the group (substituted alkyl)-OC(O)-, which is attached to the parent structure via a carbonyl functionality. Unless otherwise stated in the specification, the alkyl portions of the alkoxycarbonyl group are independently selected from alkyl, heteroalkyl, acylsulfonamido, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(Ra )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0056] "Acyl" refers to the groups (alkyl)-C(O)-, (aryl)-C(O)-, (heteroaryl)-C(O)-, (heteroalkyl)-C(O)-, and (heterocycloalkyl)-C(O)-, which are attached to the parent structure via a carbonyl functionality. When the R radical is heteroaryl or heterocycloalkyl, the heterocycle or chain atoms contribute to the total number of chain or ring atoms. Unless otherwise stated in the specification, the alkyl, aryl, or heteroaryl portions of the acyl group are independently alkyl, heteroalkyl, acylsulfonamido, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O)t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0057] "Acyloxy" refers to the R(C=O)O- radical, where R is alkyl, aryl, heteroaryl, heteroalkyl, or heterocycloalkyl, as described herein. When the R radical is heteroaryl or heterocycloalkyl, the heterocycle or chain atoms contribute to the total number of chain or ring atoms. Unless otherwise stated in the specification, the R of the acyloxy group is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R ais independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0058] "Amino" or "amine" refers to the -N(R a )2 radical groups, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl, unless otherwise stated in the specification. a ) Two groups have two R a When substituents are present, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -N(R a )2 is meant to include, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. Unless otherwise stated in the specification, amino groups are independently selected from alkyl, acylsulfonamido, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(Ra )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0059] The term "substituted amino" also refers to the group -NHR, respectively, as described above. d and N.R. d R d The N-oxides can be prepared by treatment of the corresponding amino group with, for example, hydrogen peroxide or m-chloroperbenzoic acid.
[0060] An "amide" or "amido" is a radical of the formula -C(O)NR a R b or -NR a C(O)R b R refers to a chemical moiety having a and R b is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heterocycle (bonded through a ring carbon), each of which moieties can be optionally substituted. a R b Amide R a and R bcan optionally be taken together with the nitrogen to which they are attached to form a 4-, 5-, 6-, or 7-membered ring. Unless otherwise stated herein, the amide group is optionally substituted with one or more of the substituents described herein, independently, for alkyl, amino, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl. The amide can be an amino acid or peptide molecule that is attached to the compounds disclosed herein, thereby forming a prodrug. The procedures and specific groups for making such amides are known to those skilled in the art and can be easily found in well-known sources, such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999 (incorporated herein in its entirety by reference).
[0061] "Aromatic" or "aryl" or "Ar" refers to an aromatic ring system having 6 to 10 ring atoms (e.g., C6-C8) with at least one ring having a conjugated pi-electron system that is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl). 10 Aromatic or C6-C 10It refers to aromatic radicals, including aryl. Divalent radicals formed from substituted benzene derivatives and having free valences at ring atoms are named as substituted phenylene radicals. Divalent radicals derived from monovalent polycyclic hydrocarbon radicals ending in "-yl" by removing one hydrogen atom from the carbon atom having a free valence are named by appending "-ylidene" to the name of the corresponding monovalent radical, e.g., a naphthyl group having two points of attachment is called naphthylidene. Whenever it appears herein, a numerical range such as "6 to 10" refers to each integer within the given range, e.g., "6 to 10 ring atoms" means that the aryl group can consist of up to 10 (inclusive) ring atoms, such as 6 ring atoms, 7 ring atoms, etc. The term includes monocyclic or fused ring polycyclic (i.e., rings sharing adjacent pairs of ring atoms) groups. Unless otherwise stated in the specification, aryl moieties are independently selected from alkyl, heteroalkyl, acylsulfonamido, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O)t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0062] "Aralkyl" or "arylalkyl" refers to an (aryl)alkyl-radical, where the aryl and alkyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for the aryl and alkyl, respectively.
[0063] "Ester" refers to a chemical radical of formula -COOR, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heterocycle (bonded through a ring carbon). Procedures and specific groups for making esters are known to those skilled in the art and can be readily found in prominent sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety. Unless otherwise specified herein, ester groups are independently selected from alkyl, acylsulfonamido, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -S(O)t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0064] "Fluoroalkyl" refers to an alkyl radical as defined above that is substituted by one or more fluoro radicals as defined above, for example, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. The alkyl portion of the fluoroalkyl radical can be optionally substituted as defined above for an alkyl group.
[0065] "Halo", "halide", or alternatively "halogen" is intended to mean fluoro, chloro, bromo, or iodo. The terms "haloalkyl", "haloalkenyl", "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl, and alkoxy structures that are substituted with one or more halo groups or combinations thereof. For example, the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, where the halo is fluorine.
[0066] "Heteroalkyl", "heteroalkenyl", and "heteroalkynyl" refer to optionally substituted alkyl, alkenyl, and alkynyl radicals having one or more skeletal chain atoms selected from atoms other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus, or combinations thereof. Numerical ranges may be given, e.g., C1-C4 heteroalkyl refers to the entire chain length, in this example 4 atoms long. Heteroalkyl groups are independently selected from alkyl, heteroalkyl, alkenyl, alkynyl, acylsulfonamido, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(Ra )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a 2, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0067] "Heteroalkylaryl" refers to an -(heteroalkyl)aryl radical, where the heteroalkyl and aryl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for heteroalkyl and aryl, respectively.
[0068] "Heteroalkylheteroaryl" refers to a -(heteroalkyl)heteroaryl radical, where the heteroalkyl and heteroaryl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for heteroalkyl and heteroaryl, respectively.
[0069] "Heteroalkylheterocycloalkyl" refers to a -(heteroalkyl)heterocycloalkyl radical, where the heteroalkyl and heterocycloalkyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for heteroalkyl and heterocycloalkyl, respectively.
[0070] "Heteroalkylcycloalkyl" refers to a -(heteroalkyl)cycloalkyl radical, where the heteroalkyl and cycloalkyl are as disclosed herein and are optionally substituted with one or more of the substituents described as suitable substituents for heteroalkyl and cycloalkyl, respectively.
[0071] "Heteroaryl" or "heteroaromatic" or "HetAr" refers to a 5- to 18-membered aromatic radical (e.g., C5-C6) that contains one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. 13Heteroaryl) refers to a monocyclic, bicyclic, tricyclic, or tetracyclic ring system. Each time it appears herein, a numerical range such as "5 to 18" refers to each integer within the given range, for example, "5 to 18 ring atoms" means that the heteroaryl group can consist of 5 ring atoms, 6 ring atoms, and so on up to and including 18 ring atoms. Divalent radicals derived from monovalent heteroaryl radicals whose names end in "-yl" by removing one hydrogen atom from the atom with the free valence are named by appending "-yden" to the name of the corresponding monovalent radical, for example, a pyridyl group with two points of attachment is a pyridylidene. An N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. Polycyclic heteroaryl groups can be fused or non-fused. The heteroatom(s) of the heteroaryl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. Heteroaryl may be attached to the remainder of the molecule through any atom of the ring(s). Examples of heteroaryl include azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, and the like. benzofurazanyl, benzothiazolyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furo[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl , isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, isoxazol-3-one, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, Phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazo linyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl, and thiophenyl (i.e., thienyl). Unless otherwise stated in the specification, heteroaryl moieties are independently alkyl, acylsulfonamido, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR, a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0072] Substituted heteroaryl also includes ring systems that are substituted with one or more oxide (-O-) substituents, such as, for example, pyridinyl N-oxides.
[0073] "Heteroarylalkyl" refers to a moiety having an aryl moiety, as described herein, bound to an alkylene moiety, as described herein, where the bond to the remainder of the molecule is through the alkylene group.
[0074] "Heterocycloalkyl" refers to a stable 3- to 18-membered non-aromatic cyclic radical containing 2 to 12 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. Each time it appears herein, a numerical range such as "3 to 18" refers to each integer within the given range, for example, "3 to 18 ring atoms" means that the heterocycloalkyl group can consist of 3 ring atoms, 4 ring atoms, and so on up to and including 18 ring atoms. Unless otherwise stated herein, a heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system that can include fused or bridged ring systems. The heteroatoms of the heterocycloalkyl radical can be optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl radical is partially or fully saturated. The heterocycloalkyl can be attached to the remainder of the molecule through any atom of the ring(s). Examples of such heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise stated in the specification, heterocycloalkyl moieties are independently selected from alkyl, acylsulfonamido, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, hydroxamate, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR a , -SR a , -S(O) t R a -(t is 1 or 2), -OC(O)-Ra , -N(R a )2, -C(O)R a , -C(O)OR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2), or -PO(OR a Optionally, each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0075] "Heterocycloalkyl" also includes bicyclic ring systems in which one non-aromatic ring typically has 3 to 7 ring atoms and contains at least 2 carbon atoms, as well as 1 to 3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, and a combination containing at least one of the foregoing heteroatoms, and the other ring typically has 3 to 7 ring atoms and optionally contains 1 to 3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, and is not aromatic.
[0076] "Hydroxamate" is -C(O)NR aOR a Each R refers to a part a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl.
[0077] "Nitro" refers to the -NO2 radical.
[0078] "Oxa" refers to the --O- radical.
[0079] "Oxo" refers to the =O radical.
[0080] "Isomers" are different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space, i.e., have different stereochemical configurations. Enantiomers are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. The term "(±)" is used to refer to a racemic mixture, if applicable. "Diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When a compound is a pure enantiomer, the stereochemistry at each chiral carbon can be specified by either (R) or (S). Resolved compounds of unknown absolute configuration can be specified as (+) or (-), depending on the direction (dextrorotatory or levorotatory) that they rotate plane-polarized light at the wavelength of the sodium D line. Some of the compounds described herein may contain one or more asymmetric centers and therefore give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined in terms of absolute stereochemistry as (R) or (S). The present chemical compounds, pharmaceutical compositions, and methods are meant to include all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other geometrically asymmetric centers, unless otherwise specified, it is intended that the compounds include both E and Z geometric isomers.
[0081] As used herein, "enantiomeric purity" refers to the relative amount expressed as a percentage of the presence of a particular enantiomer relative to the other enantiomer.For example, when a compound that can potentially have (R)- or (S)-isomeric configuration exists as a racemic mixture, the enantiomeric purity is about 50% for either (R)- or (S)-isomer.When the compound has one isomeric form that is more prevalent than the other (e.g., 80% (S)-isomer and 20% (R)-isomer), the enantiomeric purity of the compound for the (S)-isomeric form is 80%. The enantiomeric purity of a compound can be determined by several methods known in the art, including, but not limited to, chromatography using a chiral support, polarimetry of rotation of polarized light, nuclear magnetic resonance spectroscopy using chiral shift reagents (including, but not limited to, lanthanide-containing chiral complexes or sparkling reagents), or derivatization of the compound with a chiral compound (such as Mosher's acid) followed by chromatography or nuclear magnetic resonance spectroscopy.
[0082] In some embodiments, enantiomerically enriched compositions have higher therapeutic utility per unit mass than the racemic mixture of the composition.Enantiomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and chiral salt formation and crystallization, or preferred enantiomers can be prepared by asymmetric synthesis.See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions, Wiley Interscience, New York (1981); EL Eliel, Stereochemistry of Carbon Compounds, McGraw-Hill, New York (1962); and EL Eliel and SH Wilen, Stereochemistry of Organic Compounds, Wiley-Interscience, New York (1994).
[0083] The terms "enantiomerically enriched" and "non-racemic" as used herein refer to a composition in which the weight percent of one enantiomer is greater than the amount of that one enantiomer in a control mixture of racemic composition (e.g., greater than 1:1 weight percent). For example, an enantiomerically enriched preparation of an (S)-enantiomer refers to a preparation of a compound having more than 50% by weight (such as at least 75% by weight, or such as 80% by weight) of the (S)-enantiomer relative to the (R)-enantiomer. In some embodiments, the enrichment can be significantly greater than 80% by weight, providing a "substantially enantiomerically enriched" or "substantially non-racemic" preparation, referring to a preparation of a composition having at least 85% by weight (such as at least 90% by weight, or such as at least 95% by weight) of one enantiomer relative to the other enantiomer. The terms "enantiomerically pure" or "substantially enantiomerically pure" refer to a composition that contains at least 98% of a single enantiomer and less than 2% of the opposite enantiomer.
[0084] "Moiety" refers to a specific segment or functional group of a molecule. A chemical moiety is often a recognized chemical entity that is embedded in or appended to a molecule.
[0085] "Tautomers" are structurally distinct isomers that interconvert by tautomerization. "Tautomerization" is a form of isomerization and includes prototropic tautomerization or proton shift tautomerization, which are considered a subset of acid-base chemistry. "Prototropic tautomerization" or "proton shift tautomerization" involves the migration of a proton with a change in bond order, often involving the exchange of a single bond with an adjacent double bond. When tautomerization is possible (e.g., in solution), a chemical equilibrium of tautomers can be achieved. An example of tautomerization is keto-enol tautomerization. A specific example of keto-enol tautomerization is the interconversion of the tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1H)-one tautomers.
[0086] A "leaving group or atom" is any group or atom that will cleave from a starting material under the selected reaction conditions, thus facilitating reaction at a particular site. Examples of such groups, unless otherwise specified, include halogen atoms and mesyloxy, p-nitrobenzenesulfonyloxy, and tosyloxy groups.
[0087] "Protecting group" is intended to mean a group that selectively blocks one or more reactive sites in a polyfunctional compound, so that a chemical reaction can be selectively carried out at an otherwise unprotected reactive site, and then the group can be easily removed or deprotected after the selective reaction is complete. Various protecting groups are disclosed, for example, in TH Greene and PG M Huts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, New York (1999).
[0088] "Solvate" refers to a compound that is physically associated with one or more molecules of a pharma- ceutically acceptable solvent.
[0089] "Substituted" means that the referenced group may have one or more additional groups, radicals, or moieties attached thereto, such as acyl, alkyl, alkylaryl, cycloalkyl, aralkyl, aryl, carbohydrate, carbonate, heteroaryl, heterocycloalkyl, hydroxamate, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, ester, thiocarbonyl, isocyanato, thiocyanato, isothiocyanato, nitro, oxo, perhaloalkyl, perfluoroalkyl, phosphate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, and amino (including mono- and di-substituted amino groups), and their protected derivatives. The substituents themselves may be substituted, for example, a cycloalkyl substituent may itself have a halide substituent at one or more of its ring carbons. The term "optionally substituted" means optional substitution with the specified group, radical, or moiety.
[0090] "Sulfanyl" refers to groups including: -S-(optionally substituted alkyl), -S-(optionally substituted aryl), -S-(optionally substituted heteroaryl), and -S-(optionally substituted heterocycloalkyl).
[0091] "Sulfinyl" refers to groups including: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-(optionally substituted amino), -S(O)-(optionally substituted aryl), -S(O)-(optionally substituted heteroaryl), and -S(O)-(optionally substituted heterocycloalkyl).
[0092] "Sulfonyl" refers to groups including, -S(O2)-H, -S(O2)-(optionally substituted alkyl), -S(O2)-(optionally substituted amino), -S(O2)-(optionally substituted aryl), -S(O2)-(optionally substituted heteroaryl), and -S(O2)-(optionally substituted heterocycloalkyl).
[0093] "Sulfonamidyl" or "sulfonamide" refers to the -S(=O)2-NRR radical, where each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heterocycle (bonded through a ring carbon). The R group of -NRR of the -S(=O)2-NRR radical, together with the nitrogen to which it is attached, may form a 4-, 5-, 6-, or 7-membered ring. The sulfonamide group is optionally substituted with one or more of the substituents described for alkyl, cycloalkyl, aryl, and heteroaryl, respectively.
[0094] "Sulfoxyl" refers to the -S(=O)2OH radical.
[0095] "Sulfonate" refers to the radical -S(=O)2-OR, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heterocycle (bonded through a ring carbon). The sulfonate group is optionally substituted on R with one or more of the substituents described for alkyl, cycloalkyl, aryl, heteroaryl, respectively.
[0096] The compounds of the present invention also include crystalline and amorphous forms of the compounds, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, nonsolvated polymorphs (including anhydrous), conformational polymorphs, and amorphous forms, and mixtures thereof. "Crystalline forms" and "polymorphs" are intended to include all crystalline and amorphous forms of the compounds, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, nonsolvated polymorphs (including anhydrous), conformational polymorphs, and amorphous forms, and mixtures thereof, except when a specific crystalline or amorphous form is referred to.
[0097] p38 mitogen-activated protein kinase (MAPK), its inhibition, and selective inhibition of p38α The p38 mitogen-activated protein kinase (MAPK) family of stress- and cytokine-activated kinases contributes to the pathogenesis of many human diseases, including cancer, rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), and acute lung injury (ALI). Of the many important biological processes regulated by p38 MAPK, regulation of endothelial and epithelial barrier function, leukocyte trafficking, and cytokine expression are central to the pathogenesis of acute and chronic inflammatory disorders. Preclinical studies support the pharmacological inhibition of p38 as a promising treatment for inflammatory diseases, but p38 inhibitors have had very limited success in clinical trials due to dose-limiting toxicity and lack of efficacy. Of 36 Phase II clinical trials of p38 inhibitors listed on www.clinicaltrials.gov, results from only eight studies have been published or listed on ClinicalTrials.gov, demonstrating little clinical benefit and moderate toxicity.
[0098] All available p38 inhibitors block catalytic activity by either directly competing for ATP binding or allosterically inducing a conformational change that prevents ATP from accessing the catalytic site. Davidson et al. identified CMPD1, a purported p38α substrate-selective inhibitor, which selectively inhibited MK2 phosphorylation in in vitro kinase assays but was shown to bind near the p38α active site and subsequently lack substrate selectivity in cells. Nearly all available inhibitors are active against both p38α and p38β, and some are also active against additional isoforms. However, genetic and pharmacological studies have identified p38α as the proinflammatory isoform, while other studies have demonstrated that p38β signaling is cytoprotective. Thus, inhibition of p38β may contribute to both the lack of efficacy and toxicity of nonisoform-selective p38 inhibitors. However, the broad structural conservation of catalytic modules across most protein kinases presents a challenge in developing catalytic inhibitors with high selectivity, particularly for individual p38 isoforms.
[0099] Without wishing to be bound by any particular theory, it is believed that even if catalytic inhibitors are absolutely selective for p38α, by design, these compounds block all p38α signaling events, many of which are essential for re-establishing and maintaining homeostasis. For example, p38α not only activates the expression of pro-inflammatory cytokines, but also activates anti-inflammatory cytokines and counter-regulatory dual specificity protein phosphatase-2 (DUSP2) through MSK1 / 2, a substrate of p38α. The temporary reduction and subsequent rebound in serum C-reactive protein (CRP) levels seen in clinical trials of p38 catalytic inhibitors may be caused by the loss of MSK1 / 2-dependent anti-inflammatory signaling.
[0100] As an alternative to catalytic inhibitors, in some embodiments, the compounds and methods of the present invention target a substrate-binding groove of p38α that extends between the two acidic patches, the CD domain and the ED domain, distinct from the DEF substrate-binding pocket. Downstream substrates, upstream activating kinases, and possibly scaffolding molecules all interact with p38 through these sites. In some embodiments, computer-aided drug design (CADD) and / or rational design are used to target low molecular weight compounds to a pocket near the p38αED substrate-binding site, while anti-inflammatory MSK1 / 2 binds to the CD site. The p38αED substrate-binding site is required for phosphorylation of the p38α substrate MAPK-activated protein kinase-2 (MAPKAPK2, MK2), which is known to mediate endothelial permeability and transendothelial migration (TEM) of neutrophils in vitro and pulmonary edema in a mouse lung injury model. Using this algorithm, p38α-binding compounds with high efficiency were identified. This compound stabilizes endothelial barrier function in human pulmonary microvascular endothelial cells (HMVECL), inhibits LPS-induced proinflammatory gene expression in THP1 cells, and may be well tolerated and more potent than SB203580 in alleviating experimental ALI.
[0101] Acute Lung Injury Treated with p38α MAPK Inhibitors and Methods Described Herein Acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure with a mortality rate of 30-40% and a lack of effective treatment options. p38 signaling is important in the pathogenesis of ARDS, but clinical trials of p38 inhibitors have been disappointing due to dose-limiting toxicity, as all p38 inhibitors inactivate the catalytic site of p38 and block phosphorylation of all p38 substrates.
[0102] Acute respiratory distress syndrome (ARDS) is characterized by the acute onset of nonhydrostatic pulmonary edema, primarily due to neutrophil-mediated damage to the alveolar epithelium and dysfunction of the capillary endothelial barrier. The complex network of pro- and anti-inflammatory mediators activated with ARDS is critical to the pathogenesis of acute lung injury (ALI), as well as the multiple organ failure that often accompanies ARDS. However, therapeutic agents targeting proinflammatory mediators have proven ineffective in ARDS. Lung parenchymal damage leads to reduced compliance, intrapulmonary shunting, and ventilation-perfusion mismatch, usually resulting in the need for mechanical ventilation. However, the cyclic recruitment / derecruitment of alveoli and hyperinflation caused by mechanical ventilation itself can cause neutrophil-dependent inflammation and lung injury even to previously normal lungs. This understanding of the mechanism has led to a phase III randomized clinical trial demonstrating that low tidal volume mechanical ventilation improves survival in patients with ARDS. Two additional supportive strategies have been shown to improve mortality in patients with severe ARDS, neuromuscular blockade and prone positioning. A third intervention, restrictive fluid management, was shown to reduce time on mechanical ventilation and length of ICU stay, but did not reduce mortality. Despite these improvements in supportive care, mortality in patients with ARDS remains at 30-40% in the United States, with approximately 74,500 deaths per year, highlighting the importance of developing new therapeutic agents that target relevant pathogenetic mechanisms.
[0103] p38 mitogen-activated protein kinases (MAPKs) are a family of stress- and cytokine-activated kinases that are activated by many of the pathogenic signals associated with ARDS, including inflammatory mediators, thermal hyperthermia (FRH), and cyclic stretch. This MAPK family presents an interesting therapeutic target in ARDS because p38MAPKs are activated in patients at risk for ARDS and, as discussed below, p38MAPKs are involved in multiple processes that contribute to the pathogenesis of ARDS. As proof of concept, SB203580, a prototypic pyridinylimidazole compound, has been shown to inhibit the kinase activity of p38α and p38β, but not p38γ or p38δ, blocking multiple processes that contribute to the pathogenesis of ARDS. Endothelial p38 signaling is activated by neutrophil binding and is required for neutrophil transendothelial migration (TEM). Crosslinking ICAM-1 on human umbilical vein endothelial cells (HUVEC) stimulates p38α activation, HSP27 phosphorylation, F-actin reorganization, ICAM-1 aggregation, and cell stiffening, and increases neutrophil migration to HUVEC cell-cell junctions, all of which are blocked by SB203580. Crosslinking E-selectin on HUVEC activates p38 and p38-dependent cytoskeletal reorganization, stress fiber formation, and neutrophil TEM. Similarly, ligation of ICAM-1 to β2 integrin on neutrophils activates neutrophil p38 and p38-dependent chemokinesis and chemotaxis. Pretreatment with a p38 inhibitor was protective in mouse models of lung injury associated with ventilator-induced lung injury, complement-induced lung injury, and the gut perforation model of sepsis, but not against hemorrhage- and endotoxemia-induced lung injury. Excessive impairment of endothelial barrier function caused by FRH (a 2-3 °C increase in core temperature) in experimental ALI was shown to be associated with p38 activation and blocked by SB203580. The efficacy of SB203580 in mitigating acute lung injury, as well as multiple pathogenic processes that contribute to the relatively high expression of p38α and p38β in human lungs, supports a central role for these two p38 isoforms in the development of ARDS.
[0104] Despite these compelling preclinical data, only one clinical trial has attempted to evaluate p38 inhibition as a therapeutic strategy in ARDS. This early Phase IIa trial of SB-681323 / dilmapimod in patients at risk for ARDS (clinicaltrials.gov number NCT00996840) showed that dilmapimod was safe at the dose administered and moderately reduced serum C-reactive protein (CRP) levels, but was not powered to analyze effects on the incidence or severity of ARDS. Currently, www.clinicaltrials.gov lists a total of 74 clinical trials of p38 inhibitors, including 26 Phase I, 47 Phase II, and one Phase III study. Phase II and III trials have tested the safety and efficacy of 10 different p38 catalytic inhibitors for 13 different diseases / indications, including analgesia (6 studies), osteoarthritis (2 studies), rheumatoid arthritis (13 studies), Alzheimer's disease (2 studies), ankylosing spondylitis (1 study), cardiomyopathy (1 study), psoriasis (2 studies), atherosclerosis (5 studies), depression (2 studies), COPD (8 studies), ARDS risk (1 study), cancer (4 studies), and glomerulosclerosis (1 study). Although only a portion of the data is in the public domain, the failure of most of these drugs appears to be due to side effect profiles or lack of efficacy at the doses used. Of the 48 Phase II and III trials, 36 have been completed and 3 have been terminated early, but the results of only 8 studies have been published or listed on ClinicalTrials.gov. Two trials of VX-702 in rheumatoid arthritis showed a small increase in the proportion of treated subjects with ACR20 symptom scores versus placebo. Of two published studies of p38 inhibitors for pain, one reported a mild reduction in pain and the other had no effect. Of two published studies of p38 inhibitors in COPD, one showed no effect and the other showed an increase in FEV1 per 100 ml and a reduction in serum CRP levels in the treatment group, but with associated toxicities (rash, pharyngitis, QTc prolongation). GW85655 (losmapimod) improved vasorelaxation and reduced serum CRP in patients with hypercholesterolemia.In a ninth clinical trial, not listed on clinicaltrials.gov, BIRB796 (dorampimod) had no clinical benefit but transiently reduced serum CRP levels in patients with Crohn's disease. Collectively, these studies demonstrate the therapeutic potential of p38 inhibition in a wide range of human diseases, but highlight the limited efficacy of currently available p38 inhibitors at doses that can be safely administered to humans.
[0105] p38 MAPK shares a conserved bilobed structure and catalytic site, similar to most protein kinases, with its hydrophobic ATP-binding pocket located between the N- and C-terminal lobes. Most available protein kinase inhibitors compete with ATP for binding to the ATP-binding pocket of the catalytic site, but the extensive structural conservation of the catalytic module across most protein kinases presents a challenge for the development of catalytic p38 inhibitors with high specificity. SB203580, a pyridinylimidazole inhibitor, has been used as a specific inhibitor of p38α and p38β, as it binds to the ATP-binding site of p38α and p38β, but its access to the ATP-binding site of p38γ and p38δ is blocked by a bulky methionine. However, proteomic analysis has revealed sub-μM IC 50 Several additional kinases inhibited by SB203580 were identified in , including Rip-like interacting caspase-like apoptosis-regulating protein kinase (RICK / Rip2), casein kinase (CK)-1δ, and cyclin G-associated kinase (GAK).
[0106] A high-throughput biochemical screen for p38 inhibitors has uncovered a new class of diaryl urea compounds. Rather than binding directly to the ATP-binding pocket, these compounds bind to an allosteric site that induces a conformational change in p38 that prevents access of ATP to the ATP-binding pocket of the catalytic site. Three allosteric p38 inhibitors, BIRB796 / dolmapimod, GW856553 / rosmapimod, and SB-681323 / dilmapimod, have entered clinical trials but, like the ATP-competitive forms, have not progressed beyond Phase II trials, with the exception of the LATITUDE trial and the ongoing Phase III trial of losmapimod in patients with acute coronary syndromes (clinicaltrials.gov, number NCT02145468). These compounds inhibit all four p38 isoforms, as allosteric inhibitors are not affected by the presence of the gatekeeper methionine, but BIRB796 also has an IC of 0.1 μM. 50 and Jnk2α2 at 1.4 μM IC 50 The lack of specificity of ATP-competitive and allosteric inhibitors of p38 is likely a major cause of off-target toxicity.
[0107] An equally important source of toxicity for p38 inhibitors likely derives from the broad range of functions of each p38 MAPK isoform. Both types of inhibitors block the catalytic site of p38, and therefore ATP-competitive and allosteric inhibitors block all p38 phosphorylation events. Because p38 phosphorylates at least 66 known substrates with important biological activity, dose-limiting toxicity may be unavoidable with these agents.
[0108] MAPKp38 and ERK family members share a structural feature, a substrate-binding groove located in the C-terminal lobe of the protein opposite the catalytic domain. The binding groove extends between two acidic patches, the CD and ED domains. This region of p38 not only binds p38 substrates, but also binds upstream kinases and scaffolding proteins. Our group previously developed a new class of ERK1 / 2 MAPK inhibitors with improved toxicity profiles by using computer-aided drug design (CADD) to identify small molecules that target the substrate-binding groove rather than the catalytic module of ERK2. As described herein, a similar strategy can be used to identify low molecular weight compounds that target a pocket near the ED substrate-binding site of p38α, which is required for phosphorylation of MK2, a p38 substrate known to mediate pulmonary endothelial permeability and pulmonary edema in vitro in a mouse lung injury model. CADD was used to search a database of commercially available compounds to identify 150 low molecular weight compounds predicted to bind to a target pocket near the ED binding site of the p38α target. From this list, 20 structurally distinct compounds were obtained and screened for selective binding to p38α but not ERK2 by differential scanning fluorometry (DSF) and then analyzed for their ability to reduce pathogenic endothelial barrier alterations in human pulmonary microvascular endothelial cells (HMVECL), reduce cytokine expression in THP1 monocytes in vitro, and attenuate ALI induced in mice. Of the 20 CADD-selected compounds tested, five bound to p38α with sufficient affinity to be detected by DSF, two selectively bound to p38α but not ERK2, and they were more effective than SB203580 in stabilizing endothelial barrier function in vitro, and one of these compounds was well tolerated and more potent than SB203580 in attenuating experimental ALI.
[0109] In certain embodiments, the p38α MAPK inhibitors described herein may be used in the treatment of acute respiratory distress syndrome (ARDS) and / or acute lung injury (ALI).
[0110] p38α MAPK inhibitors and methods for inhibiting p38α MAPK In one embodiment, the present invention includes compounds that can be p38α MAPK inhibitors and / or modulators of p38α MAPK protein activity, including, for example, compounds that can bind to the pocket near the ED substrate docking site of p38α MAPK, or pharma- ceutically acceptable salts, solvates, hydrates, cocrystals, or prodrugs thereof. In one embodiment, the p38α MAPK inhibitor is a selective inhibitor of p38α MAPK. In one embodiment, the p38α MAPK inhibitor binds to p38α MAPK near the substrate binding groove of p38α MAPK that extends between the two acidic patches, the CD domain and the ED domain. In another embodiment, the p38α MAPK inhibitor causes inhibition of phosphorylation of MK2.
[0111] In one embodiment, lead compounds of p38α MAPK inhibitors are identified that have favorable biological effects in human cell culture models and mouse models of inflammatory lung injury. In one embodiment, p38α MAPK inhibitors are identified by CADD strategy. The CADD target pocket of p38α differs from the corresponding pocket of p38β by 3 out of 10 amino acids, providing an opportunity for p38α selectivity. In some embodiments, the sequence of the target pocket includes at least amino acids R49, H107, L108, and K165 of p38α MAPK. In some embodiments, the sequence of the target pocket is R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK. In one embodiment, p38α MAPK inhibitors are identified by rational design strategy.
[0112] In some embodiments, the p38α MAPK inhibitor is a compound of formula A, or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof: [ka] In formula A, Ar and Ar 1is independently selected from monocyclic or polycyclic optionally substituted cycloalkyl, monocyclic or polycyclic optionally substituted heterocycloalkyl, monocyclic or polycyclic optionally substituted aryl, monocyclic or polycyclic optionally substituted arylalkyl, monocyclic or polycyclic optionally substituted heteroaryl, and monocyclic or polycyclic optionally substituted heteroarylalkyl; R 1 and R 2 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; R 1 and R 2 can be optionally linked to form a carbocyclic or heterocyclic ring; L 1 and L 2 are independently a bond, -NR a -, -S-, -S(O)-, -S(O)2-, -O-, -CR a 2-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(O)NR a -, -NR a C(O)-, -C(O)NR a SO2-, -SO2NR a C(O)-, -OC(O)O-, -OC(O)S-, -SC(O)O-, -OC(O)NR a -, -NR a C(O)O-, -S(O) t N(R a )-(t is 1 or 2), -N(R a )S(O) t-(t is 1 or 2), a linker comprising one or more of disubstituted alkyl, disubstituted heteroalkyl, disubstituted alkenyl, disubstituted alkynyl, disubstituted cycloalkyl, disubstituted heterocycloalkyl, disubstituted aryl, disubstituted arylalkyl, disubstituted heteroaryl, and disubstituted heteroarylalkyl, any optional substituent being independently selected at each occurrence from optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -SC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)SR a , -OC(O)N(R a )2, -C(O)N(R a )2, -N(R a )C(O)OR a , -N(R a )C(O)R a , -N(R a )C(O)N(R a )2, -N(R a )C(NR a )N(R a )2, -N(R a )S(O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N(R a )2 (t is 1 or 2), and PO3 (Ra )2, and R a is independently selected at each occurrence from hydrogen, optionally substituted alkyl, optionally substituted fluoroalkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl. In some embodiments, the optional substituents are independently selected from R 3 , R 4 , R 5 , and R 6 are selected from, independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 Any two of may be optionally linked to form a carbocycle or a heterocycle. 1 is an optionally substituted aryl ring or an optionally substituted heteroaryl ring. In some embodiments, Ar is a monocyclic or polycyclic optionally substituted aryl, a monocyclic or polycyclic optionally substituted arylalkyl, a monocyclic or polycyclic optionally substituted heteroaryl, or a monocyclic or polycyclic optionally substituted heteroarylalkyl. In some embodiments, Ar is a 5- or 6-membered optionally substituted aryl, or a 5- or 6-membered optionally substituted heteroaryl, and L 1 and L 2is linked to Ar in a 1,2, 1,3, or 1,4 substitution pattern. In some embodiments, Ar is a 1,2-, 1,3-, or 1,4-disubstituted phenyl, pyridine, pyrimidine, pyrazine, or triazine. In some embodiments, Ar is a 1,2-, or 1,3-disubstituted furan, thiophene, pyrrole, thiazole, imidazole, oxazole, triazole, or pyrazole. In some embodiments, Ar is a 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, or 1,8-disubstituted naphthalene, quinoline, isoquinoline, or quinazoline. In some embodiments, Ar is a 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, or 1,7-disubstituted indole or imidazole. In some embodiments, L 1 is a linker selected from -CH2-, -C(CH3)2-, and -C(CH2CH2)-; L 2 is a linker selected from -NHCH2-, -CH2NH-, -NHCO-, -CONH-, -SO2NH-, and -NHSO2-; 1 R 2 teeth, [ka] Selected from R 7 is hydrogen or optionally substituted alkyl; Ar 2 is a heterocycle.
[0113] In one embodiment, the p38α MAPK inhibitor is a compound of formula I, or a pharma- ceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, [ka]
[0114] In formula I, R 1 , R 2 , R 3 , R 4 , R 5 , and R6 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; 1 and R 2 can be optionally linked to form a carbocyclic or heterocyclic ring; L 1 is a linker selected from -CH2-, -C(CH3)2-, and -C(CH2CH2)-; L 2 is a linker selected from -NHCH2-, -CH2NH-, -NHCO-, -CONH-, -SO2NH-, and -NHSO2-; Ar 1 is an optionally substituted aryl ring or an optionally substituted heteroaryl ring. In some embodiments, -NR 1 R 2 The group is selected from [ka] In the formula, R 7 is hydrogen or optionally substituted alkyl; Ar 2 In some embodiments, the -NR of formula I is 1 R 2 The group is selected from the following: [ka] In some embodiments, L 1 is -CH-. In some embodiments, R 3 , R 4 , R 5 , and R 6 is hydrogen. In some embodiments, L 2 is selected from -NHCH2-, -NHCO-, and -NHSO2-. 1 is selected from: [ka] In the formula, R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 each independently represents hydrogen, halogen, -NR 1 R 2 , alkoxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 Any two vicinal rings of Ar can be optionally linked to form a carbocyclic or heterocyclic ring. 1 is selected from: [ka]
[0115] In one embodiment, the p38α MAPK inhibitor is a compound of formula II, which may be selected from any one of the compounds of formulas 1001-1180 in Table 1. [ka] [Table 2-1] [Table 2-2] [Table 2-3]
Table 2-4
Table 2-5
Table 2-6
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
Table 2-12
Table 2-13
Table 2-14
Table 2-15
Table 2-16
Table 2-17
[0116] In one embodiment, the p38α MAPK inhibitor is any compound of formula 1001 (SF-6-221), 1032 (SF-7-008), SF-7-009, 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), and 1087 (SF-7-044). [Table 3-1] [Table 3-2]
[0117] Using complementary techniques, we confirmed the selective binding of UM101 to p38α. DSF detected ligand-induced protein stabilization and showed that UM101 caused a concentration-dependent increase in the melting temperature of p38α, but not p38β (Figure 3). D). The small effect of UM101 on p38α melting compared to SB203580 suggests a low p38α binding affinity of substrate-selective inhibitors relative to catalytic inhibitors, similar to substrate-selective ERK inhibitors. The smaller effect of SB203580 on p38β compared to p38α is consistent with the known affinity of SB203580 for p38α, which is approximately 10-fold higher. STD-NMR, which measures low-affinity protein:ligand binding via nonscalar magnetization transfer from protein to ligand protons, confirmed specific UM101 binding to p38α, with the interaction localized to its aromatic ring. UM101 binding to its CADD target was also confirmed by showing that mutating 4 of 10 amino acids in the target pocket abolished UM101 binding while maintaining SB203580 binding.
[0118] In some embodiments, the p38α MAPK inhibitor causes a concentration-dependent increase in the melting temperature of p38α MAPK. The difference in melting temperature ΔTm (°C) is measured at a p38α MAPK inhibitor concentration of 1 nM to 1000 μM. In one embodiment, the difference in melting temperature ΔTm (°C) is measured at a p38α MAPK inhibitor concentration of 100 μM. In one embodiment, ΔTm is about 0.1 to about 2°C. In one embodiment, ΔTm is about 0.01 to about 0.05°C. In one embodiment, ΔTm is about 0.01 to about 0.1°C. In one embodiment, ΔTm is about 0.03 to about 0.7°C. In one embodiment, ΔTm is about 0.06 to about 1.5°C. In one embodiment, ΔTm is about 1°C to about 2°C. In one embodiment, ΔTm is about 1.5 to about 2°C. In one embodiment, ΔTm is about 0.1° C. In one embodiment, ΔTm is about 0.2° C. In one embodiment, ΔTm is about 0.3° C. In one embodiment, ΔTm is about 0.4° C. In one embodiment, ΔTm is about 0.5° C. In one embodiment, ΔTm is about 0.6° C. In one embodiment, ΔTm is about 0.7° C. In one embodiment, ΔTm is about 0.8° C. In one embodiment, ΔTm is about 0.9° C. In one embodiment, ΔTm is about 1° C. In one embodiment, ΔTm is about 1.1° C. In one embodiment, ΔTm is about 1.2° C. In one embodiment, ΔTm is about 1.3° C. In one embodiment, ΔTm is about 1.4° C. In one embodiment, ΔTm is about 1.5° C. In one embodiment, ΔTm is about 1.6° C. In one embodiment, ΔTm is about 1.7° C. In one embodiment, ΔTm is about 1.8° C. In one embodiment, ΔTm is about 1.9° C. In one embodiment, the ΔTm is about 2° C. In one embodiment, the ΔTm is about 0.735° C. In one embodiment, the ΔTm is about 0.667° C.
[0119] In some embodiments, the p38α MAPK inhibitor has a logP of about -5 to about 10. In some embodiments, the p38α MAPK inhibitor has a logP of about -3 to about 8. In some embodiments, the p38α MAPK inhibitor has a logP of about 0 to about 5. In some embodiments, the p38α MAPK inhibitor has a logP of about 0.1 to about 3. LogP is a measure of drug solubility and is defined as the logarithm of the octanol / water partition coefficient of the drug. In one embodiment, the p38α MAPK inhibitor has a logP of about 0.1 to about 1. In one embodiment, the p38α MAPK inhibitor has a logP of about 0.5 to about 1.5. In one embodiment, the p38α MAPK inhibitor has a logP of about 0.75 to about 2. In one embodiment, the p38α MAPK inhibitor has a logP of about 1 to about 2.5. In one embodiment, the p38α MAPK inhibitor has a logP of about 1.75 to about 3. In one embodiment, the p38α MAPK inhibitor has a logP of about 0.1. In one embodiment, the p38α MAPK inhibitor has a logP of about 0.25. In one embodiment, the p38α MAPK inhibitor has a logP of about 0.5. In one embodiment, the p38α MAPK inhibitor has a logP of about 0.75. In one embodiment, the p38α MAPK inhibitor has a logP of about 1. In one embodiment, the p38α MAPK inhibitor has a logP of about 1.25. In one embodiment, the p38α MAPK inhibitor has a logP of about 1.5. In one embodiment, the p38α MAPK inhibitor has a logP of about 1.75. In one embodiment, the p38α MAPK inhibitor has a logP of about 2. In one embodiment, the p38α MAPK inhibitor has a logP of about 2.25. In one embodiment, the p38α MAPK inhibitor has a logP of about 2.5. In one embodiment, the p38α MAPK inhibitor has a log P of about 2.75. In one embodiment, the p38α MAPK inhibitor has a log P of about 3. In one embodiment, the p38α MAPK inhibitor has a log P of about 0.28. In one embodiment, the p38α MAPK inhibitor has a log P of about 2.31.
[0120] Phosphorylation of MK2 requires binding to the ED site adjacent to the CADD target pocket in p38α MAPK. In some embodiments, the target pocket is defined by at least amino acids R49, H107, L108, and K165 of p38α MAPK. In some embodiments, the target pocket is defined by amino acids selected from the group consisting of R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK, and combinations thereof. In some embodiments, the target pocket is defined by amino acids R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK. Western blot analysis confirmed partial inhibition of MK2 phosphorylation in anisomycin-stimulated HeLa cells by UM101, but was less than that of 10 μM SB203580, which had IC 50 Concentrations 200- and 20-fold higher than MK2 failed to completely block MK2 phosphorylation in HeLa cells, which may reflect a contribution from p38γ or p38δ, as both isoforms are expressed.
[0121] In one embodiment, the present invention relates to a method for inhibiting p38α MAPK, whereby inhibition of p38α MAPK stabilizes endothelial or epithelial barrier function. Both selective p38α binding compounds, UM60 and UM101, exerted SB203580-like endothelial barrier stabilizing and macrophage cytokine modulating effects, validating the ED targeting strategy. UM101 exerted a greater effect on MK2 phosphorylation than SB203580 (Figure 2). A and Figure 2 B) stabilized the endothelial barrier more effectively than TNFα and hyperthermia, either separately or in combination, followed by measurement of permeability to 10 kDa dextran. In one embodiment, endothelial barrier stabilization can be assessed by pretreatment with a compound of the invention followed by measurement of permeability, and stabilization is expressed as a % reduction in the increase in permeability before and after pretreatment. Pretreatment with a p38α MAPK inhibitor can be performed at various concentrations, e.g., 10, 25, 50, or 100 μM. In one embodiment, the increase in permeability to 10 kDa dextran can be reduced by 5% to more than 100%. In one embodiment, the increase in permeability is reduced by about 5%. In one embodiment, the increase in permeability is reduced by about 10%. In one embodiment, the increase in permeability is reduced by about 20%. In one embodiment, the increase in permeability is reduced by about 30%. In one embodiment, the increase in permeability is reduced by about 40%. In one embodiment, the increase in permeability is reduced by about 50%. In one embodiment, the increase in permeability is reduced by about 60%. In one embodiment, the increase in permeability is reduced by about 70%. In one embodiment, the increase in permeability is reduced by about 80%. In one embodiment, the increase in permeability is reduced by about 90%. In one embodiment, the increase in permeability is reduced by about 100%. In one embodiment, the increase in permeability is reduced by more than about 100%. In one embodiment, the increase in permeability is reduced by about 71%. In one embodiment, the increase in permeability is reduced by about 74%. In one embodiment, the increase in permeability is reduced by about 89%. In one embodiment, the increase in permeability is reduced by about 100%.
[0122] Despite its small effect on MK2 phosphorylation, UM101 significantly increased the phosphorylation rate of SB203580 (Fig. 2 A and Figure 2 B ) stabilized the endothelial barrier more effectively than C), additional molecular actions were assessed by comparing the effects of UM101 and SB203580 on global gene expression using RNASeq in TNFα-treated HMVECL. TNFα increased expression of 511 genes by more than 2-fold, of which 61 were reduced, and 38 were increased by pretreatment with 10 μM SB203580. Despite using >10-fold concentrations of UM101 required to stabilize barrier function in HMVECL (Figure 2 A and Figure 2 B ), UM101 modified the expression of only 38 of the 99 SB203580-modified genes. PathwayNet analysis showed that UM101 blocked only 7 of the 15 SB203580-blocked transcription factors. MSK1 / 2 were among those spared by UM101, which is advantageous given the anti-inflammatory effects of MSK1 / 2 and is consistent with the targeting strategy of UM101 to the site of ED.
[0123] The partial functional overlap of UM101 and SB203580 revealed by RNASeq is consistent with the design of UM101 as a noncatalytic substrate-selective inhibitor, but may also be the result of off-target effects of SB203580, including receptor-interacting protein kinase-2, cyclin G-associated kinase, and casein kinase-1 delta. However, none of the SB203580-inhibited transcription factors identified by PathwayNet analysis are known substrates of these kinases as analyzed using PhosphoNetworks.
[0124] Although the high concentrations of UM101 used in this analysis may have caused some p38-independent effects, the data presented here support the conclusion that UM101 exerts its biological effects primarily by modifying p38α: (1) DSF and STD-NMR indicate p38α-specific binding of UM101, (2) p38α binding of UM101 is abolished by mutating 4 of the 10 target pocket amino acids, (3) both UM60 and UM101 bind p38α and have effects on endothelial function similar to SB203580, (4) UM101 partially blocked phosphorylation of p38 substrates MK2 and Stat-1 in TNFα-stimulated HeLa cells, and (5) UM101 inhibited expression of approximately half of the genes inhibited by SB203580. UM101 may be more effective than SB203580 in stabilizing the endothelial barrier. This is due to the selective sparing of potential counter-regulatory genes, such as GM-CSF, MSK1 / 2-dependent anti-inflammatory genes, and p38β-dependent pro-survival genes.
[0125] In one embodiment, the present invention relates to a method of inhibiting p38α MAPK, comprising contacting p38α MAPK with a compound capable of binding to a pocket near the ED substrate docking site of p38α MAPK, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof. In one embodiment, the compound selectively inhibits p38α MAPK. In one embodiment, the p38α MAPK inhibitor binds to p38α MAPK near the substrate binding groove of p38α MAPK that extends between two acidic patches, the CD domain and the ED domain. In one embodiment, the binding pocket is defined by at least residues R49, H107, L108, and K165 of p38α MAPK. In one embodiment, the binding pocket is defined by residues R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK. In some embodiments, the p38α MAPK inhibitor causes a concentration-dependent increase in the melting temperature of p38α MAPK, hi other embodiments, the p38α MAPK inhibitor causes inhibition of phosphorylation of MK2. In one embodiment, the compound is any of the compounds of formula A, formula I, formula II, formulas 1001-1180, in particular any of the compounds of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
[0126] In one embodiment, the present invention relates to a method for inhibiting p38α MAPK, where inhibition of p38α MAPK does not result in loss of p38α-dependent counterregulatory response. In some embodiments, the p38α-dependent counterregulatory response is related to mitogen and stress-activated protein kinase-1 (MSK1) or MSK2. When targeting the pocket near the ED substrate docking site of p38α, the inhibitors described herein avoid interference with CD-specific substrates, including MSK1 / 2, thus limiting inflammation via expression of IL-10 and DUSP2. Among the effects of MSK1 / 2 deletion in mice is increased and prolonged LPS-induced expression of IL-6, a CRP regulator, suggesting a possible mechanism for the rebound of serum CRP observed in some clinical trials of catalytic p38 inhibitors.
[0127] In one embodiment, the present invention relates to a method of inhibiting p38α MAPK, whereby the inhibition of p38α MAPK reduces inflammation. In one embodiment, the effect of p38α MAPK inhibitors on inflammatory cytokine expression is compared by pretreating PMA-differentiated THP1 cells with p38α MAPK inhibitors, then stimulating with LPS, harvesting RNA after a period of time, and analyzing with a PCR-based cytokine array. In some embodiments, p38α MAPK inhibitors inhibit the expression of various genes, such as IL-1A, IL-8, TNFSF8, CXCL5, CCL7, CCL17, TNFSF9, IL-1B, CXCL1, TNFSF15, CCL5, CCL4, CCL20, CXCL2, TNF, or BMP6. In some embodiments, p38α MAPK inhibitors inhibit the expression of Smad3, which drives the differentiation of Foxp3 T regulatory cells and suppresses interferon-γ. The p38α MAPK inhibitor can be used at any suitable concentration (e.g., 10, 25, 50, or 100 μM). In one embodiment, the reduction in inflammation is measured by comparing the fold change in mRNA levels at various concentrations of the p38α MAPK inhibitor with unstimulated PMA-differentiated THP1 cells.
[0128] In some embodiments, p38α MAPK inhibitor regulates TNFα-induced gene expression in HMVECL, as demonstrated by using RNASeq.In one embodiment, HMVECL is pretreated with p38α MAPK inhibitor at appropriate concentration (e.g., 10 μM or 100 μM) for a certain period of time, and then stimulated with TNFα for a certain period of time.The p38α MAPK inhibitor of the present invention inhibits genes such as PRRG4, TSLP, CCL17, EXOC3L4, MMP9, IDO1, CXCL10, CD200, SLC15A3, VDR, IL1B, GPR88, CD207, TCHH, HAS3, GBP1P1, MUC4, ELOVL7, CXCL11, GBP4, PLA1A, or CXCL5.
[0129] In one embodiment, the present invention relates to a method of inhibiting p38α MAPK, thereby reducing lung injury in a subject, including but not limited to LPS-induced lung injury. In one embodiment, the efficacy of p38α MAPK inhibitors in reducing transalveolar protein and neutrophil extravasation in a mouse model of LPS / hyperthermia-induced ALI was compared ( FIG. 2 ). C and Figure 2 D). In one embodiment, the subject receives intraperitoneal injection(s) of p38α MAPK inhibitor at a concentration of 100, 250, 300, 400, 500, 750, 1000 μg, etc. in a suitable carrier (e.g., DMSO) for a period of time prior to intratracheal instillation of LPS and / or transfer to a thermal chamber. Lung lavage fluid from the subject is measured for protein and / or neutrophils. Lavage protein concentration and neutrophil content are reduced in subjects pretreated with p38α MAPK inhibitor compared to control subjects. In some embodiments, the reduction is about 5% to about 100%. In one embodiment, the reduction is greater than about 5%. In one embodiment, the reduction is greater than about 10%. In one embodiment, the reduction is greater than about 20%. In one embodiment, the reduction is greater than about 30%. In one embodiment, the reduction is greater than about 40%. In one embodiment, the reduction is greater than about 50%. In one embodiment, the reduction is greater than about 60%. In one embodiment, the reduction is greater than about 70%. In one embodiment, the reduction is greater than about 80%. In one embodiment, the reduction is greater than about 90%. In one embodiment, the reduction is about 100%. In one embodiment, the reduction is less than about 10%. In one embodiment, the reduction is less than about 20%. In one embodiment, the reduction is less than about 30%. In one embodiment, the reduction is less than about 40%. In one embodiment, the reduction is less than about 50%. In one embodiment, the reduction is less than about 60%. In one embodiment, the reduction is less than about 70%. In one embodiment, the reduction is less than about 80%. In one embodiment, the reduction is less than about 90%. In one embodiment, the reduction is about 100%. In one embodiment, the reduction is about 44.1%. In one embodiment, the reduction is about 43.9%. In one embodiment, the reduction is about 92.9%. In one embodiment, the reduction is about 44.4%. In one embodiment, the reduction is about 49.5%. In one embodiment, the reduction is about 55.3%. In one embodiment, the reduction is about 54%.
[0130] In one embodiment, the present invention relates to a method of inhibiting p38α MAPK, thereby modulating leukocyte trafficking.
[0131] In one embodiment, the present invention relates to a method of inhibiting p38α MAPK, thereby modulating cytokine expression.
[0132] Treatment method The compounds and compositions described herein can be used in methods for treating disease.In some embodiments, the compounds and compositions described herein can be used in methods for treating diseases associated with upregulation and / or downregulation of p38α MAPK protein.
[0133] In one embodiment, the present invention relates to a method of treating a disease alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a p38α MAPK inhibitor, the p38α MAPK inhibitor being a compound capable of binding to a pocket near the ED substrate docking site of p38α MAPK, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof. In one embodiment, the binding pocket is defined by at least residues R49, H107, L108, and K165 of p38α MAPK. In one embodiment, the binding pocket is defined by residues R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK. In one embodiment, the p38α MAPK inhibitor is a compound of any of formulas A, I, II, 1001-1180, in particular any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof. In some embodiments, the p38α MAPK inhibitor is a selective inhibitor of p38α MAPK.
[0134] In one embodiment, the invention relates to a method of treating a disease that is alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a p38α MAPK inhibitor in a dosage unit form, which in one embodiment comprises a physiologically compatible carrier medium.
[0135] In one embodiment, the present invention relates to a method of treating a disease that is alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a p38α MAPK inhibitor, wherein the disease is cancer or an inflammatory disease. In some embodiments, the disease is rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), or acute lung injury (ALI). In one embodiment, the disease is a hyperproliferative disease. In some embodiments, the hyperproliferative disorder is cancer. In some embodiments, the cancer is selected from the group consisting of pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain cancer, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung cancer, small cell lung cancer, Wilms' tumor, cervical cancer, testicular cancer, bladder carcinoma, pancreatic carcinoma, gastric cancer, colon carcinoma, prostatic cancer, carcinoma), genitourinary cancer, thyroid cancer, esophageal cancer, myeloma, multiple myeloma, adrenal cancer, renal cell carcinoma, endometrial cancer, adrenal cortical carcinoma, malignant pancreatic insulinoma, malignant carcinoid cancer, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, osteosarcoma, primary macroglobulinemia, or retinoblastoma.In other embodiments, the cancer is acoustic neuroma, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chordoma, choriocarcinoma, colon cancer, colorectal cancer, craniopharyngeal carcinoma, cystadenocarcinoma, embryonal carcinoma, endothelioma, ependymoma, epithelial carcinoma, esophageal carcinoma, Ewing's tumor, fibrosarcoma, gastric cancer, glioblastoma multiforme, glioma, head and neck cancer. Cancer, hemangioblastoma, hepatocellular carcinoma, kidney cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, nasal cancer, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma, retinoblastoma tumor, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, gastric cancer, sweat gland carcinoma, synovium, testicular cancer, small cell lung cancer, pharyngeal cancer, uterine cancer, Wilms' tumor, blood cancer, acute erythroleukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monoblastic leukemia, acute myeloblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute promyelocytic leukemia, acute anaplastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, multiple myeloma, heavy chain disease, Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, polycythemia vera, or Waldenstrom's macroglobulinemia.
[0136] In some embodiments, the hyperproliferative disorders (eg, cancer) treated by the compounds and compositions described herein include cells that have expression of p38α MAPK protein and / or p38α MAPK-related proteins.
[0137] In one embodiment, the present invention relates to a method of treating a disease that can be alleviated by inhibiting p38α MAPK protein in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a p38α MAPK inhibitor, the p38α MAPK inhibitor being a compound capable of binding to a pocket near the ED substrate docking site of p38α MAPK, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, and one or more additional therapeutic agents (including chemotherapeutic and / or immunotherapeutic agents).
[0138] The efficacy of the compounds and combinations of compounds described herein in treating the indicated diseases or disorders can be tested using various models known in the art and described herein, which provide guidance for the treatment of human diseases. Any and all of the described treatment methods can include medical follow-up to determine the therapeutic or prophylactic effect produced in the subject treated with the compound(s) and / or composition(s) described herein.
[0139] Pharmaceutical Compositions In one embodiment, the active pharmaceutical ingredient or combination of active pharmaceutical ingredients (eg, any of the p38α MAPK inhibitors of the present invention) is provided as a pharma- ceutically acceptable composition.
[0140] In one embodiment, the present invention relates to a pharmaceutical composition, comprising a therapeutically effective amount of a p38α MAPK inhibitor, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, and a physiologically compatible carrier medium, for treating a disease that is alleviated by inhibiting the activity of p38α MAPK in a patient in need thereof, wherein the p38α MAPK inhibitor is a compound capable of binding to a pocket near the ED substrate docking site of p38α MAPK. In one embodiment, the binding pocket is defined by at least residues R49, H107, L108, and K165 of p38α MAPK. In one embodiment, the binding pocket is defined by residues R49, H107, L108, M109, G110, A157, V158, E163, L164, and K165 of p38α MAPK. In one embodiment, the p38α MAPK inhibitor is a compound of any of formulas A, I, II, 1001-1180, in particular any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof. In some embodiments, the p38α MAPK inhibitor is a selective inhibitor of p38α MAPK.
[0141] In one embodiment, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a p38α MAPK inhibitor, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, and a physiologically compatible carrier medium, for treating a disease that is alleviated by inhibiting the activity of p38α MAPK in a patient in need thereof, the disease being cancer or an inflammatory disease. In one embodiment, the disease is rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), or acute lung injury (ALI). In one embodiment, the disease is acoustic neuroma, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chordoma, choriocarcinoma, colon cancer, colorectal cancer, craniopharyngeal carcinoma, cystadenocarcinoma, embryonal carcinoma, endothelioma, ependymoma, epithelial carcinoma, esophageal carcinoma, Ewing's tumor, fibrosarcoma, gastric cancer, glioblastoma multiforme, glioma, head and neck cancer. , hemangioblastoma, hepatocellular carcinoma, kidney cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, nasal cancer, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma, retinoblastoma, Cancers such as sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, gastric cancer, sweat gland carcinoma, synovium, testicular cancer, small cell lung cancer, pharyngeal cancer, uterine cancer, Wilms' tumor, blood cancer, acute erythroleukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monoblastic leukemia, acute myeloblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute promyelocytic leukemia, acute anaplastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, multiple myeloma, heavy chain disease, Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, polycythemia vera, or Waldenstrom's macroglobulinemia.
[0142] In some embodiments, the active pharmaceutical ingredient provided in the pharmaceutical composition of the invention, e.g., any of the active pharmaceutical ingredients of the p38α MAPK inhibitors of the invention, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly any of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), may be present in, for example, 100%, 90%, 80%, 100% or more of the pharmaceutical composition. 0%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02% , less than 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (w / w, w / v, or v / v).
[0143] In some embodiments, the active pharmaceutical ingredient provided in the pharmaceutical composition of the invention, e.g., any of the active pharmaceutical ingredients of the p38α MAPK inhibitors of the invention, e.g., any of the compounds of formula A, formula I, formula II, formulas 1001-1180, particularly formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-01 2), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) are each present in a concentration of 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, or 19.5% of the pharmaceutical composition. 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%,4.75%,4.50%,4.25%,4%,3.75%,3.50%,3.25%,3%,2.75%,2.50%,2.25%,2%,1.75%,1.50%,125%,1%,0.5%,0.4%,0.3%,0.2%,0.1%,0.09%,0.08%,0.07%,0.06%,0.05%,0.04%,0 .03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.More than 0.001% (w / w, w / v, or v / v).
[0144] In some embodiments, the active pharmaceutical ingredient provided in the pharmaceutical composition of the invention, e.g., any of the active pharmaceutical ingredients of the p38α MAPK inhibitors of the invention, e.g., any of the compounds of formula A, formula I, formula II, formula 1001-1180, in particular, any of the compounds of formula 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044). The concentration of each of the active pharmaceutical ingredients may be from about 0.0001% to about 50%, from about 0.001% to about 40%, from about 0.01% to about 30%, from about 0.02% to about 29%, from about 0.03% to about 28%, from about 0.04% to about 27%, from about 0.05% to about 26%, from about 0.06% to about 25%, from about 0.07% to about 24%, from about 0.08% to about 23% of the pharmaceutical composition. , about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12%, or about 1% to about 10% (w / w, w / v, or v / v).
[0145] In some embodiments, the active pharmaceutical ingredient provided in the pharmaceutical composition of the invention, e.g., any of the active pharmaceutical ingredients of the p38α MAPK inhibitors of the invention, e.g., any of the compounds of formula A, formula I, formula II, formula 1001-1180, particularly formula 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 106 The concentration of each of the active pharmaceutical ingredients of any of SF-6-219, 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) is within the range of about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to about 1%, about 0.1% to about 0.9% (w / w, w / v, or v / v) of the pharmaceutical composition.
[0146] In some embodiments, the active pharmaceutical ingredient provided in the pharmaceutical composition of the invention is, for example, any of the aforementioned p38α MAPK inhibitors of the invention, such as any of the compounds of formula A, formula I, formula II, formulas 1001-1180, particularly formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 ( The amount of each of the active pharmaceutical ingredients in any of SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) is 10g, 9.5g, 9.0g, 8.5g, 8.0g, 7.5g, 7.0g, 6.5g, and 6. 0g, 5.5g, 5.0g, 4.5g, 4.0g, 3.5g, 3.0g, 2.5g, 2.0g, 1.5g, 1.0g, 0.95g, 0.9g, 0.85g, 0.8g, 0.75g, 0.7g, 0 .65g, 0.6g, 0.55g, 0.5g, 0.45g, 0.4g, 0.35g, 0.3g, 0.25g, 0.2g, 0.15g, 0.1g, 0.09g, 0.08g, 0.07g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0 ...06 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g.
[0147] In some embodiments, the active pharmaceutical ingredient provided in the pharmaceutical composition of the invention is, for example, any of the p38α MAPK inhibitors of the invention, for example, any of the compounds of formula A, formula I, formula II, formulas 1001-1180, particularly formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-221), 1044 (SF-6-222), 1045 (SF-6-222), 1046 (SF-6-222), 1047 (SF-6-222), 1048 (SF-6-222), 1049 (SF-6-222), 1050 (SF-6-222), 1051 (SF-6-222), 1052 (SF-6-222), 1053 (SF-6-222), 1054 (SF-6-222), 1055 (SF-6-222), 1056 (SF-6-222), 1057 (SF-6-222), 1058 (SF-6-222), 1059 (SF-6-222), 1060 (SF-6-222), 1061 (SF-6-222), 1062 (SF-6-222), 1063 (SF-6-222), 1064 (SF-6-222), 1065 (SF-6-222), 1066 (SF-6-222), 1067 (SF-6-222), 1068 (SF- F-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) are each in an amount of 0.0001g, 0.0002g, 0.0003g, 0.0004g, 0.0005g, 0.0006g, 0.0007g, 0.0008g, 0.0009g, 0.001g, 0.0015g, 0.002g, 0.0025g, 0.003 ... g, 0.003g, 0.0035g, 0.004g, 0.0045g, 0.005g, 0.0055g, 0.006g, 0.0065g, 0.007g, 0.0075g, 0.008g, 0.0085g, 0.009g, 0. 0095g, 0.01g, 0.015g, 0.02g, 0.025g, 0.03g, 0.035g, 0.04g, 0.045g, 0.05g, 0.055g, 0.06g, 0.065g, 0.07g, 0.075g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or greater than 10 g.
[0148] Each of the active pharmaceutical ingredients according to the present invention is effective over a wide dosage range. For example, in the treatment of adult humans, dosages ranging from 0.01 to 1000 mg, 0.5 to 100 mg, 1 to 50 mg, and 5 to 40 mg per day are examples of dosages that may be used, independently. The exact dosage will depend on the route of administration, the form in which the compound is administered, the sex and age of the subject being treated, the weight of the subject being treated, and the preference and experience of the attending physician. Clinically established dosages of the p38α MAPK inhibitors of the present invention may also be used as needed.
[0149] In one embodiment, the molar ratio of the two active pharmaceutical ingredients in the pharmaceutical composition ranges from 10:1 to 1:10, preferably from 2.5:1 to 1:2.5, more preferably about 1:1. In one embodiment, the weight ratio of the molar ratio of the two active pharmaceutical ingredients in the pharmaceutical composition is selected from the group consisting of 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, and 1:20. In one embodiment, the weight ratio of the molar ratio of the two active pharmaceutical ingredients in the pharmaceutical composition is selected from the group consisting of 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, and 1:20.
[0150] In one embodiment, the pharmaceutical compositions described herein, e.g., any of the p38α MAPK inhibitors of the present invention, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, in particular, any of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), are used to treat inflammatory diseases. In one embodiment, the pharmaceutical compositions described herein (e.g., any of the p38α MAPK inhibitors of the present invention) are used to treat rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), or acute lung injury (ALI).
[0151] In one embodiment, the pharmaceutical compositions described herein, e.g., any of the p38α MAPK inhibitors of the present invention, e.g., any of the compounds of formula A, formula I, formula II, formula 1001-1180, in particular, any of formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), are used to treat hyperproliferative disorders associated with overexpression or upregulation and / or downregulation of p38α MAPK protein.In some embodiments, the pharmaceutical compositions described herein are useful for treating cancers associated with overexpression or upregulation and / or downregulation of p38α MAPK protein (e.g., pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain cancer, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung cancer, small cell lung cancer, Wilms' tumor, cervical cancer, testicular cancer, bladder carcinoma, pancreatic carcinoma, gastric cancer, colon carcinoma, prostatic cancer, carcinoma), genitourinary cancer, thyroid cancer, esophageal cancer, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortical carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, osteosarcoma, primary macroglobulinemia, or retinoblastoma).
[0152] Listed below are non-limiting pharmaceutical compositions and methods for their preparation.
[0153] Pharmaceutical Compositions for Oral Administration In one embodiment, the present invention provides a pharmaceutical composition for oral administration, comprising an active pharmaceutical ingredient or a combination of active pharmaceutical ingredients, such as a p38α MAPK inhibitor as described herein, and a pharmaceutical excipient suitable for oral administration.
[0154] In some embodiments, the present invention provides solid pharmaceutical compositions for oral administration, comprising (i) an effective amount of an active pharmaceutical ingredient or combination of active pharmaceutical ingredients, and (ii) a pharmaceutical excipient suitable for oral administration. In selected embodiments, the composition further comprises (iii) an effective amount of a third active pharmaceutical ingredient, and optionally, (iv) an effective amount of a fourth active pharmaceutical ingredient.
[0155] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral ingestion. The pharmaceutical composition of the present invention suitable for oral administration may be presented in separate dosage forms, such as capsules, sachets, or tablets, or liquids or aerosol sprays, each containing a predetermined amount of active ingredient as a powder or in granules, solutions, or suspensions in aqueous or non-aqueous liquids, oil-in-water emulsions, water-in-oil liquid emulsions, powders for reconstitution, powders for oral ingestion, bottles (containing powders or liquids in the bottles), orally dissolvable films, lozenges, pastes, tubes, gums, and packs. Such dosage forms may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient(s) into association with a carrier, which constitutes one or more necessary ingredients. In general, the composition is prepared by uniformly and intimately mixing the active ingredient(s) with a liquid carrier or finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in free form (such as powder or granules), optionally mixed with excipients (such as, but not limited to, binders, lubricants, inert diluents, and / or surface active or dispersing agents. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[0156] The present invention further encompasses anhydrous pharmaceutical compositions and dosage forms, since water can accelerate the degradation of some compounds. For example, pharmaceutical techniques may add water (e.g., 5%) as a means of simulating long-term storage to determine characteristics such as shelf life or stability of a formulation over time. The anhydrous pharmaceutical compositions and dosage forms of the present invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or humidity conditions. The pharmaceutical compositions and dosage forms of the present invention containing lactose can be made anhydrous if they are expected to be in substantial contact with moisture and / or humidity during manufacture, packaging, and / or storage. The anhydrous pharmaceutical compositions can be prepared and stored such that their anhydrous nature is maintained. Thus, the anhydrous compositions may be packaged using known materials to prevent exposure to water, which can be included in suitable formulation kits. Examples of suitable packaging include, but are not limited to, sealed foils, sealed plastics, and the like, unit dose containers, blister packs, and strip packs.
[0157] Each of the active pharmaceutical ingredients can be intimately mixed and combined with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms, depending on the desired preparation form for administration. When preparing compositions for oral dosage forms, any of the usual pharmaceutical media can be used as a carrier, for example, for oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, etc. can be used as carriers, or for oral solid preparations, starch, sugar, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc. can be used as carriers, and in some embodiments, lactose is not required to be used. For example, suitable carriers include powders, capsules, and tablets, including solid oral preparations. If necessary, tablets can be coated by standard aqueous or non-aqueous techniques.
[0158] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums (e.g., acacia), sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, calcium carboxymethylcellulose, sodium carboxymethylcellulose), polyvinylpyrrolidone, methylcellulose, pregelatinized starch, hydroxypropyl methylcellulose, microcrystalline cellulose, and mixtures thereof.
[0159] Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof.
[0160] Disintegrants may be used in the compositions of the present invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much disintegrant may produce tablets that disintegrate in the bottle. Too little may be insufficient for disintegration to occur, thus altering the rate and extent of release of the active ingredient from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much so as not to adversely alter the release of the active ingredient(s) can be used to form a dosage form of the compound disclosed herein. The amount of disintegrant used may vary based on the type of formulation and mode of administration, and can be readily understood by one of ordinary skill in the art. About 0.5 to about 15% by weight of disintegrant, or about 1 to about 5% by weight of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pregelatinized starch, other starches, clays, other algins, other celluloses, gums, or mixtures thereof.
[0161] Lubricants that can be used to form the pharmaceutical compositions and dosage forms of the present invention include, but are not limited to, calcium stearate, magnesium stearate, sodium stearyl fumarate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof. Additional lubricants include, for example, syloid silica gel, coagulated aerosol of synthetic silica, silicified microcrystalline cellulose, or mixtures thereof. Lubricants can be optionally added in an amount of less than about 0.5% by weight, or less than about 1% by weight, of the pharmaceutical composition.
[0162] When aqueous suspensions and / or elixirs are desired for oral administration, the active pharmaceutical ingredient(s) may be combined with various sweetening or flavoring agents, coloring agents or pigments, and, if necessary, emulsifying and / or suspending agents, diluents such as water, ethanol, propylene glycol, glycerin, and various combinations thereof.
[0163] Tablets may be uncoated or coated by known techniques, which delays disintegration and absorption in the digestive tract, thereby providing sustained action over a longer period of time.For example, time-delay materials such as glyceryl monostearate or glyceryl distearate can be used.Also, the preparation for oral use can be presented as a hard gelatin capsule in which active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin, or as a soft gelatin capsule in which active ingredient is mixed with an aqueous medium or an oil medium, such as peanut oil, liquid paraffin or olive oil.
[0164] Surfactants that can be used to form the pharmaceutical compositions and dosage forms of the present invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, i.e., a mixture of hydrophilic surfactants can be used, a mixture of lipophilic surfactants can be used, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant can be used.
[0165] Suitable hydrophilic surfactants may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of about 10 or less. An empirical parameter used to characterize the relative hydrophilicity and relative hydrophobicity of nonionic amphiphilic compounds is the hydrophilic-lipophilic balance ("HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic and have higher solubility in oils, while surfactants with higher HLB values are more hydrophilic and have higher solubility in aqueous solutions. Hydrophilic surfactants are generally considered to be compounds with HLB values greater than about 10, as well as anionic, cationic, or zwitterionic compounds to which the HLB scale does not generally apply. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds with HLB values of about 10 or less. However, the HLB value of surfactants is generally only a rough guide used to enable the formulation of emulsions for industrial, pharmaceutical, and cosmetic applications.
[0166] Hydrophilic surfactant can be either ionic or nonionic.Suitable ionic surfactant includes but is not limited to alkyl ammonium salt, fusidate salt, fatty acid derivatives of amino acid, oligopeptide and polypeptide, glyceride derivatives of amino acid, oligopeptide and polypeptide, lecithin and hydrogenated lecithin, lysolecithin and hydrogenated lysolecithin, phospholipid and its derivatives, lysophospholipid and its derivatives, carnitine fatty acid ester salt, alkyl sulfate salt, fatty acid salt, sodium docusate, acyl-lactylate, mono- and diacetylated tartaric acid esters of mono- and diglycerides, succinylated mono- and diglycerides, citrate esters of mono- and diglycerides and mixtures thereof.
[0167] Within the aforementioned group, ionic surfactants include, by way of example, lecithin, lysolecithin, phospholipids, lysophospholipids and their derivatives, carnitine fatty acid ester salts, alkyl sulfates, fatty acid salts, sodium docusate, acyl acrylates, mono- and diacetylated tartaric acid esters of mono- and diglycerides, succinylated mono- and diglycerides, citrate esters of mono- and diglycerides, and mixtures thereof.
[0168] Ionic surfactants include lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, and lactylic acid esters of fatty acids. The ionized forms of the glyceryl esters may be glyceryl, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono / diacetylated tartaric acid esters of mono / diglycerides, citrate esters of mono / diglycerides, cholyl sarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and mixtures thereof.
[0169] Hydrophilic nonionic surfactants include alkyl glucosides, alkyl maltosides, alkyl thioglucosides, lauryl macrogol glycerides, polyoxyalkylene alkyl ethers (e.g., polyethylene glycol alkyl ethers), polyoxyalkylene alkylphenols (e.g., polyethylene glycol alkylphenols), polyoxyalkylene alkylphenol fatty acid esters (e.g., polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters), polyethylene glycol glycerol fatty acid esters, polyglycerol fatty acid esters, polyoxyalkylene sorbitan fatty acid esters (e.g., polyethylene glycol Examples of suitable polyoxyethylene esters include, but are not limited to, glycerol sorbitan fatty acid esters, hydrophilic transesterification products of polyols (including at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols), polyoxyethylene sterols (including derivatives and analogs thereof), polyoxyethylated vitamins and their derivatives, polyoxyethylene-polyoxypropylene block copolymers and mixtures thereof, polyethylene glycol sorbitan fatty acid esters, and hydrophilic transesterification products of polyols (including at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils). The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a sugar.
[0170] Other hydrophilic nonionic surfactants include PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, Salt, PEG-20 Dilaurate, PEG-25 Glyceryl Trioleate, PEG-32 Dioleate, PEG-20 Glyceryl Laurate, PEG-30 Glyceryl Laurate, PEG-20 Glyceryl Stearate, PEG-20 Glyceryl Oleate, PEG-30 Glyceryl Oleate, PEG-30 Glyceryl Laurate, PEG-40 Glyceryl Laurate, PEG-40 Palm Kernel Oil, PEG-50 Hydrogenated Castor Oil, PEG-40 Castor Oil, PEG-35 Castor Oil, PEG-60 Castor Oil, PEG-40 Hydrogenated Castor Oil, PEG-60 Hydrogenated Castor Oil, PEG-60 Corn Oil, PEG-6 Capric / Caprylic Glycerides, PEG-8 Capric / Caprylic Glycerides, Polyglyceryl-10 Laurate, PEG-30 Cholesterol, PEG-25 Phytosterols, PEG-30 Soy Sterols, PEG-20 Trioleate, PEG-40 Sorbitan Oleate, PEG-80 Sorbitan Laurate, Polysorbate 20, Polysorbate 80, POE-9 Lauryl Ether, POE- Examples of suitable glyceryl ethers include, but are not limited to, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series, and poloxamers.
[0171] Suitable lipophilic surfactants include, by way of example only, fatty alcohols, glycerol fatty acid esters, acetylated glycerol fatty acid esters, lower alcohol fatty acid esters, propylene glycol fatty acid esters, sorbitan fatty acid esters, polyethylene glycol sorbitan fatty acid esters, sterols and sterol derivatives, polyoxyethylated sterols and sterol derivatives, polyethylene glycol alkyl ethers, sugar esters, sugar ethers, lactic acid derivatives of mono- and diglycerides, hydrophobic transesterification products of polyols (including at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols), oil-soluble vitamins / vitamin derivatives, and mixtures thereof.In this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or hydrophobic transesterification products of polyols including at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.
[0172] In one embodiment, the composition may contain a solubilizer to ensure good solubilization and / or dissolution of the compound of the present invention and minimize precipitation of the compound of the present invention. This may be particularly important for compositions for parenteral use (e.g., compositions for injection). Solubilizers may also be added to increase the solubility of hydrophilic drugs and / or other components (such as surfactants) or to maintain the composition as a stable or homogeneous solution or dispersion.
[0173] Examples of suitable solubilizing agents include, but are not limited to, alcohols and polyols (e.g., ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and its isomers, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrin and cyclodextrin derivatives), ethers of polyethylene glycol having an average molecular weight of about 200 to about 6000 (e.g., tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG), amides and other nitrogen-containing compounds (e.g., 2-pyrrolidone, 2-piperidine, 2-pyrrolidone ... Solubilizing agents such as ethyl propionate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and its isomers, δ-valerolactone and its isomers, β-butyrolactone and its isomers, and other solubilizing agents known in the art (e.g., dimethylacetamide, dimethylisosorbide, N-methylpyrrolidone, monooctanoin, diethylene glycol monoethyl ether, and water).
[0174] Mixtures of solubilizers may also be used. Examples include, but are not limited to, triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol, and propylene glycol.
[0175] The amount of solubilizer that may be included is not particularly limited. The amount of a given solubilizer may be limited to the biotolerable amount, which may be easily determined by one of ordinary skill in the art. In some circumstances, for example, to maximize the concentration of the drug, it may be advantageous to include an amount of solubilizer that far exceeds the biotolerable amount, and remove the excess solubilizer using conventional techniques such as distillation or evaporation before providing the composition to the patient. Thus, when present, the solubilizer may be in a weight ratio of 10%, 25%, 50%, 100%, or up to about 200% by weight, based on the combined weight of the drug and other excipients. If desired, very small amounts of solubilizer may also be used, for example, 5%, 2%, 1%, or even less. Typically, the solubilizer may be present in an amount of about 1% to about 100% by weight, more typically about 5% to about 25% by weight.
[0176] The composition may further comprise one or more pharma- ceutically acceptable additives and excipients, including, but not limited to, release agents, antifoaming agents, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity modifiers, tonicity agents, flavors, colorants, odorants, opacifying agents, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
[0177] In addition, acids or bases can be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium bicarbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS), etc. Also suitable are bases that are salts of pharma- ceutically acceptable acids (e.g., acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, etc.). Salts of polybasic acids such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient pharma-ceutically acceptable cation, such as ammonium, alkali metals, and alkaline earth metals. Examples can include, but are not limited to, sodium, potassium, lithium, magnesium, calcium, and ammonium.
[0178] Suitable acids are pharma- ceutically acceptable organic or inorganic acids.Suitable examples of inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, etc.Suitable examples of organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acid, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acid, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, and uric acid.
[0179] Injectable pharmaceutical composition In some embodiments, a pharmaceutical composition is provided for injection and includes an active pharmaceutical ingredient (such as a p38α MAPK inhibitor, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly any of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044)) or a combination of active pharmaceutical ingredients, and a pharmaceutical excipient suitable for injection.
[0180] Forms in which the compositions of the present invention may be incorporated for administration by injection include aqueous or oily suspensions, or emulsions (with sesame, corn, cottonseed, or peanut oil, as well as elixirs, mannitol, dextrose, or sterile aqueous solutions, and similar pharmaceutical vehicles).
[0181] Conventionally, aqueous solutions in saline are also used for injection. Ethanol, glycerol, propylene glycol and liquid polyethylene glycol (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils can also be used. Proper fluidity can be maintained, for example, by using coating agents (such as lecithin, to maintain the required particle size in the case of dispersions) and surfactants. Prevention of microbial action can be brought about by various antibacterial and antifungal agents (for example, parabens, chlorobutanol, phenol, sorbic acid, and thimerosal).
[0182] Sterile injectable solution is prepared by incorporating active pharmaceutical ingredient or combination of active pharmaceutical ingredient into appropriate solvent containing various other ingredients listed above in the required amount, and then sterilizing by filtration.Generally, dispersion is prepared by incorporating various sterilized active ingredients into a sterile vehicle that contains basic dispersion medium and other necessary ingredients listed above.For the case of sterile powder for preparing sterile injectable solution, the specific desired preparation method is vacuum drying and freeze-drying technology, which obtains powder of active ingredient and any additional desired ingredients from their solution that has been previously sterilized and filtered.
[0183] Pharmaceutical Compositions for Local Delivery In some embodiments, a pharmaceutical composition is provided for transdermal delivery and includes an active pharmaceutical ingredient (such as a p38α MAPK inhibitor as described herein, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly any of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044)) or a combination of active pharmaceutical ingredients, and a pharmaceutical excipient suitable for transdermal delivery.
[0184] The composition of the present invention can be formulated into preparations suitable for local or topical administration, such as gel, water-soluble jelly, cream, lotion, suspension, foam, powder, slurry, ointment, solution, oil, paste, suppository, spray, emulsion, saline solution, dimethyl sulfoxide (DMSO)-based solution, etc., in solid, semi-solid or liquid form.In general, carriers with higher density can provide a certain area with prolonged exposure to active ingredient.In contrast, solution formulations can provide a more immediate exposure of active ingredient to selected areas.
[0185] Pharmaceutical compositions can also include suitable solid or gel phase carriers or excipients, which are compounds that allow increased permeability of therapeutic molecules across the permeability barrier of the stratum corneum of the skin or assist in the delivery of therapeutic molecules.There are many of these penetration enhancing molecules, and they are known to those skilled in the art of topical formulations.Examples of such carriers and excipients include, but are not limited to, moisturizers (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidone, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers (such as polyethylene glycol).
[0186] Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches can be used to provide continuous or discontinuous infusion of an active pharmaceutical ingredient or a combination of active pharmaceutical ingredients, with or without another active pharmaceutical ingredient, in controlled amounts.
[0187] The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art.See, for example, U.S. Patent Nos. 5,023,252, 4,992,445, and 5,001,139, which are incorporated herein by reference in their entirety.Such patches can be constructed for continuous, pulsatile, or on-demand delivery of pharmaceutical agents.
[0188] Pharmaceutical Compositions for Inhalation Compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may comprise a suitable pharma- ceutically acceptable excipient as described above and a p38α MAPK inhibitor as described herein, such as any of the compounds of formula A, formula I, formula II, formula 1001-1180, and in particular any of the inhibitors of formula 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044). Preferably, the composition is administered by oral or nasal respiratory route for local or systemic effect.The composition, preferably in a pharmaceutically acceptable solvent, can be atomized by using inert gas.The atomized solution can be inhaled directly from the nebulizer device, or the nebulizer device can be attached to a face mask tent, or an intermittent positive pressure breathing machine.The solution, suspension, or powder composition can be administered from a device that delivers the formulation in an appropriate manner, preferably orally or nasally.Dry powder inhalers can also be used to provide inhalation delivery of the composition.
[0189] Other Pharmaceutical Compositions Pharmaceutical compositions of p38α MAPK inhibitors as described herein, such as any of the compounds of formula A, formula I, formula II, formulas 1001-1180, in particular formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1044 (SF-6-225), 1045 (SF-6-226), 1046 (SF-6-227), 1047 (SF-6-228), 1048 (SF-6-229), 1049 (SF-6-301), 1050 (SF-6-310), 1051 (SF-6-311), 1052 (SF-6-312), 1053 (SF-6-313), 1054 (SF-6-314), 1055 (SF-6-315), 1056 (SF-6-316), 1057 (SF-6-317), 1058 (SF-6-318), 1059 (SF-6-319), 1060 (SF-6-320), 1061 (SF-6-321), 1062 (SF-6-322), 1063 (SF-6-323), 1064 (SF-6-324), 1065 (SF-6-325), 1066 (SF-6-326), 1067 (SF-6-327), 1068 (SF-6-328), 1069 (SF-6-329), Pharmaceutical compositions of any of the inhibitors of SF-23), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) may also be prepared from the compositions described herein and one or more pharma- ceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, ocular, intranasal, epidural, or intraspinal administration. Preparation of such pharmaceutical compositions is well known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002, and Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, NY, 1990. (Each of which is incorporated by reference in its entirety herein).
[0190] The administration of the active pharmaceutical ingredient or combination of active pharmaceutical ingredients or pharmaceutical composition thereof can be effected by any method that allows the compound to be delivered to the site of action.These methods include oral route, intraduodenal route, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal, or infusion), topical (e.g., transdermal application), intrarectal administration, local delivery by catheter or stent, or via inhalation.The active pharmaceutical ingredient or combination of active pharmaceutical ingredients can also be administered intraadiposely or intrathecally.
[0191] Exemplary parenteral administration forms include solutions or suspensions of the active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose. Such dosage forms can be suitably buffered, if necessary.
[0192] kit The present invention also provides kits. The kits include an active pharmaceutical ingredient or combination of active pharmaceutical ingredients (either alone or in combination with suitable packaging) and written materials that may include instructions for use, clinical trial discussions, and a list of side effects. Such kits may also include information such as scientific references, package inserts, clinical trial results, and / or summaries thereof, in which the activity and / or benefits of the composition are demonstrated or established, and / or dosage, administration, side effects, drug interactions, or other information useful to health care providers. Such information may be based on the results of various studies (e.g., studies using laboratory animals, including in vivo models, and studies based on human clinical trials). The kits may further include another active pharmaceutical ingredient. In selected embodiments, the active pharmaceutical ingredient or combination of active pharmaceutical ingredients is provided as a separate composition in separate containers within the kit. In selected embodiments, the active pharmaceutical ingredient or combination of active pharmaceutical ingredients is provided as a single composition within the container of the kit. Suitable packaging and additional items for use (e.g., measuring cups for liquid preparations, foil packaging to minimize exposure to air, etc.) are known in the art and may be included in the kit. The kits described herein may be provided, marketed, and / or promoted to health care providers (including physicians, nurses, pharmacists, prescribers, etc.) The kits may also, in selected embodiments, be sold directly to consumers.
[0193] In some embodiments, the present invention provides a kit, comprising a therapeutically effective amount of an active pharmaceutical ingredient (e.g., a p38α MAPK inhibitor, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly any of the compounds of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF The kit includes a composition comprising a combination of active pharmaceutical ingredients, or a pharmacokinetic or pharmacokinetically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, of any of the following compounds: SF-6-217, 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044). These compositions are typically pharmaceutical compositions. The kit is for co-administration of the active pharmaceutical ingredients or combination of active pharmaceutical ingredients, either simultaneously or separately.
[0194] In some embodiments, the invention provides kits, the kits including: (1) a therapeutically effective amount of an active pharmaceutical ingredient (e.g., a p38α MAPK inhibitor, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly any of the compounds of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-4-10), 1044 (SF-4-11), 1045 (SF-4-12), 1046 (SF-4-13), 1047 (SF-4-14), 1048 (SF-4-15), 1049 (SF-4-16), 1050 (SF-4-17), 1051 (SF-4-18), 1052 (SF-4-19), 1053 (SF-4-19), 1054 (SF-4-19), 1055 (SF-4-19), 1056 (SF-4-19), 1057 (SF-4-19), 1058 (SF-4-19), 1059 (SF-4-19), 1060 (SF-4-19), 1061 (SF-4-19), 1062 (SF-4-19), 1063 (SF-4-19), 1064 (SF-4-19), 1065 (SF-4-19), 1066 (SF-4-19), 1067 (SF-4-19), 1068 (SF-4-19), 1069 ( (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), or a combination of active pharmaceutical ingredients, or a pharma- ceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof; and (2) a diagnostic test for determining whether a patient's cancer is a particular subtype of cancer. Any of the aforementioned diagnostic methods can be utilized in the kit.
[0195] The kit described above is preferably used for the treatment of diseases and conditions described herein.In some embodiments, the kit is used for the treatment of inflammatory diseases.In some embodiments, the kit is used for the treatment of rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS) or acute lung injury (ALI).In certain embodiments, the kit is used for the treatment of hyperproliferative disorders (e.g., cancer).
[0196] In certain embodiments, the kits described herein are used to treat cancer. In some embodiments, the kits described herein are used to treat pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain cancer, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung cancer, small cell lung cancer, Wilms' tumor, cervical cancer, testicular cancer, bladder carcinoma, pancreatic carcinoma, gastric cancer, colon carcinoma, prostatic cancer, carcinoma), genitourinary cancer, thyroid cancer, esophageal cancer, myeloma, multiple myeloma, adrenal cancer, renal cell carcinoma, endometrial cancer, adrenal cortical carcinoma, malignant pancreatic insulinoma, malignant carcinoid cancer, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, osteosarcoma, primary macroglobulinemia, and retinoblastoma. In certain embodiments, the kits described herein are used to treat malignant melanoma.
[0197] Dosage and Dosing Regimen The amount of pharmaceutical composition administered using the methods herein, e.g., a p38α MAPK inhibitor, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF The dosage of any of SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) will depend on the human or mammal being treated, the severity of the disorder or condition, the rate of administration, the kinetics of the active pharmaceutical ingredient, and the discretion of the prescribing physician. However, effective dosages range from about 0.001 to about 100 mg per kg of body weight per day (e.g., about 1 to about 35 mg / kg / day), in single or divided doses. For a 70 kg human, this would be about 0.05 to 7 g / day (e.g., about 0.05 to about 2.5 g / day). In some cases, dosage levels below the lower limit of the aforementioned range may be more than sufficient, while in other cases even larger doses may be used without causing any adverse side effects (e.g., by dividing such larger doses into several smaller doses to be administered throughout the day). Dosages of pharmaceutical compositions and active pharmaceutical ingredients are given in mg / kg body weight, or mg / m 2 It may be provided in units of body surface area.
[0198] In some embodiments, the invention includes a method of treating cancer in a human subject suffering from a cancer in which the cancer cells overexpress p38α MAPK, the method comprising administering to a human subject a therapeutically effective dose of an active pharmaceutical ingredient, i.e., a p38α MAPK inhibitor, such as any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly any of the compounds of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 103 The method includes administering to a human subject an inhibitor of any of SF-7-010, 1035, SF-7-011, 1036, SF-7-012, 1037, SF-6-217, 1043, SF-6-223, 1049, SF-6-224, 1061, SF-6-219, 1085, SF-6-222, SF-7-009, and 1087, SF-7-044.
[0199] In some embodiments, the invention includes a method of treating cancer in a human subject suffering from a cancer in which the cancer cells overexpress p38α MAPK, the method comprising administering to a subject a therapeutically effective dose of an active pharmaceutical ingredient, i.e., a p38α MAPK inhibitor, such as any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, in particular any of the compounds of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), The method includes administering to a human subject any of the following inhibitors: 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) to inhibit or reduce activity of p38α MAPK protein.
[0200] In some embodiments, the pharmaceutical composition or active pharmaceutical ingredient is administered in a single dose. Such administration may be by injection (e.g., intravenous injection) to rapidly introduce the active pharmaceutical ingredient. However, other routes (including the preferred oral route) may be used if necessary. A single dose of the pharmaceutical composition may also be used to treat acute conditions.
[0201] In some embodiments, the pharmaceutical composition or active pharmaceutical ingredient is administered in multiple doses. In one embodiment, the pharmaceutical composition is administered in multiple doses. Dosing can be once, twice, three times, four times, five times, six times, or more than six times per day. Dosing can be once a month, once every two weeks, once a week, or once every other day. In other embodiments, the pharmaceutical composition is administered about once to about six times per day. In some embodiments, the pharmaceutical composition is administered once a day, while in other embodiments, the pharmaceutical composition is administered twice a day, and in other embodiments, the pharmaceutical composition is administered three times a day.
[0202] Administration of the active pharmaceutical ingredient can continue for as long as necessary. In selected embodiments, the pharmaceutical composition is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days (multiple). In some embodiments, the pharmaceutical composition is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day (multiple). In some embodiments, the pharmaceutical composition is administered chronically on an ongoing basis, for example, for the treatment of chronic effects. In some embodiments, administration of the pharmaceutical composition continues for less than about 7 days. In yet other embodiments, administration continues for more than about 6, 10, 14, 28 days, 2 months, 6 months, or 1 year. In some cases, continuous dosing is achieved and maintained for as long as necessary.
[0203] In some embodiments, an effective dosage of an active pharmaceutical ingredient disclosed herein, e.g., any of the compounds of Formula A, Formula I, Formula II, Formulas 1001-1180, particularly any of Formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), 1037 (SF-6-217), 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044), is about 1 mg to about 500 mg, about 10 mg to about 300 mg, about 20 mg to about 250 mg. , about 25 mg to about 200 mg, about 10 mg to about 200 mg, about 20 mg to about 150 mg, about 30 mg to about 120 mg, about 10 mg to about 90 mg, about 20 mg to about 80 mg, Approximately 30mg to approximately 70mg, approximately 40mg to approximately 60mg, approximately 45mg to approximately 55mg, approximately 48mg to approximately 52mg, approximately 50mg to approximately 150mg, approximately 60mg to approximately 140mg, approximately 70 In some embodiments, the effective dosage of an active pharmaceutical ingredient disclosed herein is less than about 25 mg, less than about 50 mg, less than about 75 mg, less than about 100 mg, less than about 125 mg, less than about 150 mg, less than about 175 mg, less than about 200 mg, less than about 225 mg, or less than about 250 mg. In some embodiments, the effective dosage of an active pharmaceutical ingredient disclosed herein is greater than about 25 mg, greater than about 50 mg, greater than about 75 mg, greater than about 100 mg, greater than about 125 mg, greater than about 150 mg, greater than about 175 mg, greater than about 200 mg, greater than about 225 mg, or greater than about 250 mg.
[0204] In some embodiments, the active pharmaceutical ingredient disclosed herein is selected from the group consisting of compounds of formula A, formula I, formula II, and formulas 1001-1180, particularly formulas 1001 (SF-6-221), 1032 (SF-7-008), 1034 (SF-7-010), 1035 (SF-7-011), 1036 (SF-7-012), and 1037 (SF-6-217). , 1043 (SF-6-223), 1049 (SF-6-224), 1061 (SF-6-219), 1085 (SF-6-222), SF-7-009, and 1087 (SF-7-044) may be administered in an amount ranging from about 0.01 to about 200 mg / kg, or from about 0.1 to 100 mg / kg, or from about 1 to 50 mg / kg.
[0205] In some embodiments, the active pharmaceutical ingredient is administered at a dosage of 10-200 mg twice daily (including 50, 60, 70, 80, 90, 100, 150, or 200 mg twice daily). In some embodiments, the active pharmaceutical ingredient is administered at a dosage of 10-500 mg twice daily (including 1, 5, 10, 15, 25, 50, 75, 100, 150, 200, 300, 400, or 500 mg twice daily).
[0206] In some cases, dosage levels below the lower limit of the aforementioned range may be more than sufficient, while in other cases, even larger doses may be used without causing adverse side effects (e.g., by dividing such larger doses into several smaller doses to be administered throughout the day). Of course, as those skilled in the art will understand, the actual dosage administered will depend on the condition being treated, the age, health and weight of the recipient, the type of concurrent treatment, if any, and the frequency of treatment. Furthermore, the effective dosage can be determined by those skilled in the art based on routine empirical activity testing to measure the biological activity of the compound(s) in bioassays and thus establish the appropriate dosage to be administered.
[0207] An effective amount of the combination of active pharmaceutical ingredients may be administered by any of the accepted modes of administration of drugs having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intraarterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalation, in either single or multiple doses.
[0208] In some embodiments, the compositions described herein further include controlled, sustained, or extended release therapeutic dosage forms for administering the compounds described herein, which involve incorporating the compounds into a suitable delivery system in the formation of a particular composition. The dosage forms control the release of the compound(s) such that the effective concentration of the compound(s) in the bloodstream can be maintained over an extended period of time at a relatively constant concentration in the blood to improve therapeutic outcomes and / or minimize side effects. Additionally, the controlled release system will provide minimal peak-to-trough fluctuations in the plasma levels of the compound.
[0209] The following examples further illustrate the invention. These examples are provided for illustrative purposes only and should not be construed as limiting the invention in any way. EXAMPLES
[0210] material and method Chemicals, recombinant proteins and antibodies: Mouse anti-human p38α and rabbit anti-phosphorylated MK2 (T222) and anti-phosphorylated Stat-1 (S727) antibodies were purchased from Cell Signaling Technology (Danvers, MA). The coding sequences of human p38α variant 2 and p38β (with an N-terminal HA tag) were amplified by PCR and cloned into pRSetA (Thermo Fisher). Mutations were introduced into p38α using Quikchange (Stratagene) and confirmed by bidirectional sequencing. Plasmids were transformed into E. coli BL21 and proteins were purified using a cobalt column (TALON™; Clontech Laboratories; Mountain View, CA) and confirmed by SDS-PAGE and Western blot. Compounds identified in the CADD screen were purchased from Maybridge Chemical Co. (Belgium).
[0211] CADD identification of lead compounds (Figure 1 D ): Based on the X-ray crystal structure of mouse p38α / MAPK14 (PDB ID: 1P38), a stepwise iterative CADD process was used to screen an in silico database of small molecule compounds available from the Maybridge Chemical Screening Collection for their potential to bind in a pocket near the ED substrate binding site (Figure 1 A and Figure 1 B). In silico preparation of p38α conformation was performed using CHARMM36 and the (CGenFF) general force field with Nanoscale Molecular Dynamics (NAMD) program to identify local potential ligand-binding pockets. Protein structures were subjected to clustering to identify 20 representative protein conformations to account for protein flexibility. The screening was performed in the following stages: (1) potential inhibitor binding sites were identified, (2) compounds were ranked based on their van der Waals (VDW) energy and electrostatic interaction energy with the protein binding pocket using the program DOCK with size-based score normalization, (3) the top 50,000 compounds were subjected to a second reaction of in silico screening with further relaxation of the ligand during simulated binding, and the top 1,000 compounds were selected based on the total interaction energy including ligand size-based score normalization, (4) a cluster analysis based on the chemical fingerprints of the top scoring compounds using the program MOE (Chemical Computing Group) was performed to identify chemically diverse compounds, and a final list of potential p38α interacting compounds was selected based on 4DBA, a scalar bioavailability metric that considers physicochemical descriptors in Lipinski's rule of five.
[0212] Mouse unphosphorylated p38α / MAPK14 variant-1 differs from its human variant-2 by only two amino acids (H48L and A263T) and from mouse variant-2 and human variant-1 by only 14 amino acids between residues 230 and 254. These amino acid differences, or the phosphorylation state of p38α (Figure 1 C ) are not predicted to significantly alter the structure of the CD or ED sites or our CADD target sites, validating the use of mouse non-phosphorylated p38α variant-1 for CADD searches and non-phosphorylated recombinant human p38α variant-2 protein for DSF screening.
[0213] Site Identification by Ligand Competition Saturation (SILCS): Using the Site Identification by Ligand Competition Saturation (SILCS) method (Figure 6, potential binding sites in green), an in silico map of all potential ligand binding pockets of p38α, including the ED site target, was completed. The SILCS method creates free energy maps (Grid Free Energy; GFE FragMaps) of the functional group interaction patterns of p38α, which allows for the identification of putative binding sites and rapid free energy estimation of ligand binding to various p38α sites (ligand GFE or LGFE). The SILCS GFE FragMaps consider protein flexibility, protein desolvation, functional group desolvation, as well as functional group-protein interactions, resulting in highly accurate mapping of the protein for use in database screening and lead compound optimization. Each stepwise in silico CADD screening of any compound database starts with the SILCS pharmacophore approach, which takes into account protein flexibility. The secondary screening is based on the MC SILCS approach, where the relative free energy of binding is calculated. Final screening based on physiochemical properties maximizing chemical diversity, absorption, distribution, metabolism, and excretion (ADME) features, and potential chemical optimization generates a list of compounds to test for selective p38α binding and biological activity. Additional rounds of screening are performed using a modified CADD strategy based on proteomic and structural analysis of the lead compounds. Searching of databases for structural analogues of lead compounds from previous rounds is performed using the program MOE (Chemical Computing Group).
[0214] Alternative CADD methods: The program Dock can be used with scoring based on Dock van der Waals (vdW) interaction energies normalized to molecular weight (MW). This method identifies compounds that sterically fit into the binding site, with a bias towards low MW compounds. Further ranking of compounds uses a generalized linear response method and includes the free energy of solvation based on the implicit solvent generalized Born (GB) model.
[0215] Alternative p38α targets: The search strategy can be modified to target the CD or DEF site. Since activation of p38α is required for formation of the DEF pocket, dual phosphorylated p38α is used for the DSF screen.
[0216] Differential Scanning Fluorometry (DSF): Binding of CADD-selected compounds to p38α and p38β isoforms is experimentally tested using DSF to assess changes in melting temperature (ΔTm) of the target protein upon interaction with the test compound. SYPRO Orange (Invitrogen; diluted 1:1000 in 10 mM HEPES, 150 mM NaCl, pH 7.5) and 1 μM of unphosphorylated recombinant human p38α were added to a 96-well PCR plate, followed by addition of 50 nM to 200 μM of test compound in 100% DMSO (final DMSO concentration of 2%), the plate was mixed, sealed, centrifuged at 1000 rpm for 1 min, and melting curves were obtained using an Applied Biosystems real-time PCR instrument. Melting points were determined from first derivative curves. In addition, p38β, or target-disrupted p38α mutants were also used.
[0217] Although DSF is less sensitive than other assays for ligand:protein binding, it is low cost and has a relatively high throughput. DSF detected p38α binding in 25% of the CADD-identified compounds screened, increasing selective p38α binding by 10%, demonstrating the good efficiency of both the CADD and DSF screening strategies. The 10% hit rate of the CADD search for substrate-selective p38α inhibitors was similar to the search for substrate-selective ERK inhibitors and much greater than the typical 0.1-0.01% hit rate using only experimental screening.
[0218] Cell culture: HMVECL were purchased from Promocell (Heidelberg, DE), maintained in endothelial cell growth medium MV2, used at passages 3–10, and tested after confluence according to the supplier's protocol. THP1 human monocytic cell line (American Type Culture Collection / ATCC, no. TIB202) was maintained in RPMI1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES buffer, pH 7.3, penicillin, streptomycin, 0.05 mM β-mercaptoethanol, and 10% defined fetal bovine serum (FBS; Gibco, Life Technologies, Grand Island, NY). HeLa cells (ATCC no. CCL-2) were cultured in DMEM containing 4.5 g / L glucose, 1 mM sodium pyruvate, 2 mM L-glutamine, penicillin, streptomycin, and 10% FBS. Prior to the experiments, THP1 cells were differentiated by treating them with 5 ng / ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) for 24 h, washing with PBS, and culturing them in PMA-free medium for an additional 24 h at 37°C.
[0219] Endothelial permeability assay: Permeability of HMVECL monolayers was assessed by measuring the transendothelial flux of 10 kDa dextran conjugated to Cascade Blue fluorescent dye in Matrigel-coated 3 μm pore size Transwell plates for 30 min at 37°C.
[0220] Cells are treated with 1-100 μM test compound, 10 μM SB203580, or DMSO for 1 h, then with 10 ng / ml rhTNFα for 6 h at 39.5° C., 100 μg / ml Cascade-Blue conjugated 10 kDa dextran is added to the bottom wells for 30 min at 37° C., and permeability is assessed by analyzing the fluorescence (400 / 420 nm) of the top wells.
[0221] Neutrophil transendothelial migration (TEM) assay: Using a protocol approved by the University of Maryland Institutional Review Board, neutrophils were isolated from heparinized venous blood drawn from healthy volunteers and TEM of calcein-labeled neutrophils was measured via HMVECL.
[0222] Cytotoxicity of HMVECL exposed to 10-100 μM of each compound is analyzed by MTS assay (Promega), LDH release (Promega), and immunoblot for activated caspase-3 (Cell Signaling).
[0223] Macrophage cytokine expression: Evaluate the ability of test compounds to block LPS-induced cytokine expression in PMA-differentiated THP1 cells using qRT-PCR and Luminex-based immunoassays (UMB Cytokine Core Lab). THP1 cells differentiated with 5 ng / ml PMA for 24 h are treated with 1-100 μM test compound, 10 μM SB203580, or DMSO for 1 h, then treated with 100 ng / ml ultra-pure E. coli 0111:B4 LPS (InvivoGen) for 3 h (qRT-PCR; Real Time Primers) or 24 h (supernatants for immunoassays).
[0224] Mouse acute lung injury model: Male CD-1 mice weighing 25-30 g were purchased from Charles River and housed at the Baltimore Veterans Administration Medical Center Animal Care Facility under AALAC-approved conditions. All protocols were approved by the University of Maryland Baltimore IACUC. Inhibitors were tested via intratracheal administration (it) in mice. LPS / FRH-induced ALI model. Mice were pretreated with SB203580 or a putative p38 inhibitor (in DMSO at ≤2%) via 0.5 ml intraperitoneal (ip) injection 1 h prior to intratracheal (it) instillation of 50 μg LPS and switched to a 37°C incubator to raise the core temperature to approximately 39.5°C. Mice were euthanized 24 h later, lungs lavaged with a total of 2 ml PBS, cells were counted, and cell-free lavage fluid was analyzed for protein content using the Bradford method (Biorad).
[0225] To implant intraperitoneal thermistors, animals are anesthetized with isoflurane inhalation during surgery. Mice receive 0.05-0.1 mg / kg buprenorphine analgesia (sc) every 12 h for 2 days postoperatively. Buprenorphine analgesia is administered if significant distress occurs during the ALI model. LPS is administered in 50 μl PBS via instillation at the posterior oropharynx during isoflurane anesthesia. p38 inhibitors are administered via ip injection with a 25 g needle with conscious mice lightly restrained.
[0226] The combination of FRH and intratracheal LPS induces robust pulmonary neutrophil influx, cytokine expression, and protein leakage by 12-24 h, with 50% mortality beginning at 48 h. In this model, UM101 was more potent than SB203580 in reducing neutrophil and protein accumulation in the BAL. Therefore, to minimize the number of mice required for this screen, we measure lung injury, pulmonary and extrapulmonary inflammation, and drug toxicity at a single 24 h time point, including BAL protein, neutrophil, and proinflammatory cytokine content, serum levels of IL-6, creatinine and AST (Abcam), and cardiac troponin I (MyBiosource). Novel compounds are tested at doses of 4, 12, and 40 mg / kg and compared to vehicle (DMSO) and SB203580 (40 mg / kg) treated controls. All vehicle- and drug-treated mice were exposed to LPS / FRH (it) and compared to naïve mice. Four mice per group may be used.
[0227] Generally, screening is performed in a preventive model and final candidates are evaluated in a therapeutic model.
[0228] Inhibition of substrate phosphorylation: Functional analysis of UM101 in blocking p38-dependent phosphorylation of MK2 and Stat-1 was performed in HeLa cells. Cells were pretreated with SB203580 or UM101 for 30 min and then activated with 10 μM anisomycin for 30 min. Cell extracts prepared in RIPA buffer containing protease and phosphatase inhibitors were separated by SDS-PAGE, transferred to PVDF membranes, blocked with 5% dried skim milk, and probed with primary antibodies against phosphorylated MK2 and phosphorylated Stat-1, as well as total p38α as a loading control. Bands were detected using secondary antibodies conjugated to infrared fluorophores and infrared fluorescence imaging (Odyssey; LICOR).
[0229] Cytotoxicity Assay: Cytotoxicity was monitored in parallel on HMVEC-L monolayers formed in 96-well culture plates using a colorimetric assay that measures the reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) to a formazan dye (CellTiter96™, Promega, Madison, WI) according to the manufacturer's protocol and quantifies product formation by measuring absorbance at 490 nm.
[0230] Gene Expression: RNA integrity was confirmed by Agilent Bioanalyzer2100, and all samples were confirmed to have an RNA Integrity Score (RIN) of 10 before further analysis. Poly(A) enriched samples were reverse transcribed and sequenced using the Illumina HiSeq platform to generate at least 90 million reads per sample. Intergenic sequences accounted for less than 0.7% of all reads, indicating minimal genomic DNA contamination. Raw data was analyzed using the TopHat read alignment tool and the Homo sapiens genome reference sequence (Ensembl version GRCh38.78). Differential gene expression was analyzed using the DESeq R package (Bioconductor) and a negative binomial distribution model. Criteria for significant differences in gene expression were (1) false discovery rate (FDR) less than 0.05, (2) expression levels greater than the 10th percentile, and (3) fold change greater than or equal to 2-fold. Differential gene expression patterns were further analyzed using PathwayNet (Troyanskaya Lab, Princeton) and Ingenuity™ Pathway Analysis (Qiagen) tools. Expression of cytokine genes in THP1 cells was analyzed by quantitative RT-PCR using primers from a commercial PCR array (HCA-II array; Real Time Primers; Elkins Park, PA) and SYBR-green reaction mixtures (Biorad) and a BioRad iCycler IQ optical module according to the supplier's protocol. Data were quantified using the Ct difference method of gene expression and normalized to the levels of the housekeeping gene, GAPDH, using Ct values determined automatically by the thermocycler.
[0231] Saturation Transfer Difference Nuclear Magnetic Resonance (STD-NMR): A 40 mM stock solution of UM101 was made in d6-DMSO. STD-NMR samples contained 150 mM NaCl, 50 mM phosphate (pH 7), 200 μM UM101, and 5 μM p38 protein in D2O. Spectra were recorded on an Agilent DD2 500-MHz spectrometer equipped with a 5 mm inverted HFCN probehead at 300 K. During each transient, the protein was saturated with a series of 58 GAUSSIAN shaped pulses (50 ms, 1 ms delay between pulses) using the vendor-supplied STD-ES pulse sequence for a total saturation time of 3 s. Resonant irradiation of the protein was performed at 0.5 ppm and non-resonant irradiation was performed at 30 ppm. The water signal in the STD spectrum was suppressed using the vendor-supplied WATERGATE pulse sequence. Resonant and non-resonant pulse sequences were subtracted internally. A total of 16,384 transients were collected for each STD experiment with a 1 s delay between collections, a spectral width of 6000 Hz, and an acquisition time of 1.3 s.
[0232] Comparative proteome and phosphopeptide expression profiling by mass spectrometry (MS): Protein expression and the percentage of phosphorylation of specific proteins are quantified label-free using mass spectrometry-based techniques. Specifically, the effects of compounds of the present invention on protein phosphorylation patterns and proteome expression in TNFα-stimulated HMVECL cells and LPS-stimulated THP1 cells are compared to SB203580 using LC-MS / MS. Cells were treated with 10 μM SB203580 or EC 50 and E.C. 90Cells are pretreated with test compounds (based on HMVECL permeability and THP1 IL-8 expression assays) for 30 min. For phosphopeptide analysis, cells are stimulated for 0.5, 1.5, and 4 h. Trypsinized phosphopeptides are enriched using a commercial Tio2 enrichment protocol (Pierce) and then analyzed on a nanoUPLC-coupled Thermo Orbitrap Fusion Tribrid mass spectrometer using three strategies: (1) hybrid electron transfer (ETD) / high-energy collision (HCD) dissociation (EThcD), (2) data-dependent decision tree (DDDT) logic, (3) HCD product-dependent ETD (HCD-pd-ETD), and / or (4) ion mobility-coupled parallel mass spectrometry (UDMS). e ) on a nanoUPLC-coupled Waters Synapt G2S mass spectrometer. For comparative proteomic expression analysis, cells were stimulated for 4 and 12 h and lysates were analyzed by UDMS, respectively. E and analyzed on a nanoUPLC-coupled Waters Synapt G2S and / or a nanoUPLC-coupled Thermo Orbitrap Fusion Tribrid using ADAPT-DDA. Relative peptide abundance was measured by comparing the MS1 peak areas of peptide ions and was analyzed using the different fragmentation strategies described above (EThcD, DDDT, HCD-pd-ETD, and UDMS). e ) is used to confirm the identity and phosphorylation events by MS2 sequencing. The aligned AMRT (accurate mass and retention time) cluster quantification algorithm as described is used for label-free quantification.
[0233] Immunoblot analysis: Changes in the total in vivo proteome and phosphoproteome are identified by immunoblotting using commercial antibodies and infrared fluorescence imaging (Odyssey; LICOR). In vitro kinase assays are performed in reactions containing recombinant active p38α and one or more recombinant substrate proteins and analyzed by immunoblotting with phosphorylation site-specific antibodies.
[0234] X-ray crystallography: X-ray crystallography provides high-resolution analysis of compound binding to p38α. The primary approach for growing p38α involves co-crystallization of compound crystals with a molar ratio of 2:1 compound:p38α. Alternatively, compounds are soaked into preformed p38α crystals. Diffraction-quality protein crystals are grown and screened using an automated system including an Alchemist DT screenmaker, a Gryphon drop setter with an LCP module, and a Minstrel DT UV / Vis automated visualization system (Rigaku). These structures are solved by molecular replacement methods using known p38α structures and standard crystallography software (SBGrid).
[0235] Analysis of p38 binding kinetics: KD of the compounds of the present invention is estimated by DSF. ITC is performed to generate thermodynamic information to refine the calculation of KD of the compounds and to facilitate ligand optimization. Data is collected with an Auto ITC HT microcalorimeter (MicroCal). Recombinant p38α (10 μM) and stock concentrations of test compounds (200 μM) are prepared and degassed in the same buffer containing low ionization energy (e.g., 50 mM phosphate or 50 mM NaCl in citrate). Exotherms / endotherms during the titration of the compounds are measured and analyzed with MicroCal software.
[0236] Pharmacokinetic / pharmacodynamic (PK / PD) analysis of lead compounds: Compounds are comprehensively analyzed for in vivo toxicity and efficacy as both preventive and therapeutic in an intratracheal LPS+FRH-induced murine ALI model. This model is a short-term model of human ARDS, amenable to parenteral administration of therapeutic agents, and is characterized by extensive endothelial permeability, neutrophil accumulation, proinflammatory cytokine and chemokine expression, epithelial damage, and approximately 50% mortality beginning after 48 h. Results are generalizable to other inflammatory diseases. Compounds are solubilized in DMSO at a final concentration of 1% or less and administered as a single intraperitoneal injection. Maximum tolerated dose (MTD) is determined by monitoring mice for 24 h for signs of distress (including changes in motor activity, weight loss, reduced grooming, and bristling), creatinine, BUN, aspartate transaminase (AST), and cardiac troponin. Inhibitors are administered either 30 min before or 8 h after LPS+FRH as prophylactic or therapeutic models, respectively.
[0237] Number and sex of animals: All studies were performed in CD1 mice, a robust strain with validated ALI and pneumonia models. Dose escalation will be performed following published guidelines, using 2 mice per dose, with 24-hour observation. Differences in survival will be tested in groups of 20 mice (detecting survival differences of 75% vs. 25%, α=0.05, β=0.2). Group sizes of 6 mice will be used for BAL and plasma analysis of injury / inflammation, as well as lung homogenates for analysis of apoptosis signaling, and 4 mice per group for histology. Survival experiments will be performed with an equivalent number of male and female mice, and differences will be compared by two-way ANOVA. Additional experiments will be added to analyze any unexpected sex differences found in drug effects. In some embodiments, male mice will be used in the experiments.
[0238] The maximum tolerated dose (MTD) of the most potent structurally diverse compound is determined by measuring toxicity at 20, 40, and 80 mg / kg (ip) in two mice per dose, monitored for 24 hours, and euthanized. Serum is analyzed for markers of liver, kidney, and heart toxicity. Kidneys, heart, liver, and lungs (inflated) are fixed, paraffin embedded, stained with hematoxylin-eosin, and examined for inflammation and injury. Control mice receive vehicle (1% DMSO). The toxic compound is replaced by the next structurally diverse compound on the list of candidates.
[0239] Activity of inhibitors to block FRH-enhanced LPS-induced ALI: Compounds are tested at the MTD in the LPS- and FRH-induced ALI model.
[0240] Effect of pretreatment on survival: In LPS / FRH-challenged mice (groups of 20 mice), the efficacy of pretreatment with test compound at the MTD on survival is compared to SB203580 at 40 mg / kg and vehicle (1% DMSO). Mice receive pretreatment as a single injection of 0.5 ml and 30 minutes later receive 50 μg LPS via it instillation and placed at an ambient temperature of 37° C. This exposure increases core temperature from 36.5° C. to 39.5° C., which is confirmed in some mice using telemetric temperature monitoring (Data Sciences International; St. Paul, MN). Mice are monitored for survival using moribundity instead of death. Those compounds that show a survival advantage over DMSO are further analyzed for efficacy when administered 24 hours after LPS. Ineffective compounds are replaced with the next compound on the candidate list. Effective compounds are further tested at 10% and 30% of the MTD.
[0241] Post-LPS Effects on Viability: Compounds effective as pretreatments are analyzed for efficacy at the same dose using the same protocol, except delayed until 8 hours after LPS instillation and initiation of FRH. Compounds conferring a survival advantage over SB203580 are analyzed for biological effect and pharmacokinetics. Ineffective compounds are replaced with the next compound on the list.
[0242] Compound effects on inflammation, lung injury, and permeability: The most effective compounds in survival experiments will be further analyzed for their effects on lung injury and inflammation in the LPS+FRH ALI model. Mice were incubated at 4°C for 30 min before or 8 h after LPS / FRH challenge with ED 50 Mice are pretreated with each compound (based on survival experiments), SB203580 at 40 mg / kg, or DMSO and euthanized 24 hours after LPS. In six mice per group, BALF is collected and analyzed for neutrophil content by counting modified Giemsa-stained cytopreps, total protein by Bradford method, and cytokine levels by Luminex-based immunoassay (UMB Cytokine Core Lab). After lavage, lungs are excised, snap frozen in liquid nitrogen, and homogenates are prepared for immunoblotting of candidate p38α substrates to confirm substrate inhibitor effects found in vitro. Lungs from four mice per group are stretched / fixed at 20 cmH2O, Prefer™, paraffin embedded, hematoxylin-eosin stained, or GR-1 immunostained to analyze lung injury and neutrophil infiltration, as well as TUNEL staining and immunostaining for active caspase-3 to assess apoptosis. Serum IL-6 is measured as an indicator of systemic inflammation.
[0243] Pharmacokinetics of novel p38 modulators: In mice, characterize the pharmacokinetics (PK) of the active compounds. First, bioanalytical methods for each compound are developed and validated according to FDA guidance. Then, PK studies are performed to evaluate the pulmonary uptake and key PK parameters characterizing each compound, i.e., clearance (CL), volume of distribution (Vd), maximum plasma concentration (C max ), C maxArrival time (T max ), area under the plasma concentration curve (AUC) and half-life (t 1 / 2 ) are determined. PK parameters are used to estimate the time required to reach steady-state plasma concentrations (corresponding to 5 half-lives) and guide dose selection for further PD studies. Additionally, these studies help rank the tested p38 modulating agents in terms of lung / plasma concentration ratios. For each study, CD1 mice (n=30) are treated with a single ip dose (10-50 mg / kg) of the selected p38 modulating agent (the dose range for each p38 modulating agent depends on the results of the studies outlined above. In some embodiments, mice (n=3 / time point) are euthanized pre-dose and at 5, 15, 30, 60, 120, 240, 360, 600, 720 min post-dose. Blood and lung samples are analyzed using validated HPLC methods.
[0244] Data analysis: The pathways modified by the compounds of the present invention are estimated compared to SB203580 by: (1) analyzing comparative proteome expression using Ingenuity pathway analysis and PathwayNet, as well as RNASeq data from UM101, and (2) analyzing comparative phosphoproteomes by quantitative approaches and bioinformatics. Mass spectrometry results are confirmed by analyzing phosphorylation of candidate substrates in cells and by in vitro kinase assays with immunoblots. Off-target binding suggested by proteomics data is evaluated by DSF and STD-NMR, as well as by phosphoimmunoblots for specific substrates, and confirmed in vitro kinase reactions by evaluating test compounds over a wide concentration range. By identifying common pathways modified by multiple lead compounds and their interactions with p38α, the effect of common p38α required for their favorable biological activity is estimated and incorporated into the CADD algorithm for subsequent search and optimization of lead compounds.
[0245] Since the objective of the present invention is, in one embodiment, to identify and characterize the PD / PK properties of novel anti-inflammatory compounds, these compounds are, in one embodiment, tested in order of activity based on functional screening, and compounds that fail toxicity or efficacy in survival studies are replaced with the next most potent structurally distinct compound. Compounds are compared to vehicle alone and SB203580 using one-way ANOVA / Fisher's PLSD. PK data are analyzed by naive mean methods. Compartmental modeling is used to estimate various pharmacokinetic parameters using the Phoenix platform (ver. 1.3, Pharsight, Sunnyvale, CA). Several compartmental models are evaluated to determine the best-fitting model. Equal weighting, 1 / y, 1 / y^, 1 / y 2 , and 1 / y^ 2 Various weighting schemes are used, including: (where y is the observed drug concentration and y^ is the model-predicted drug concentration). In some embodiments, the final model is selected based on goodness-of-fit plots, weighted sum of squared residuals, random distribution of residuals, precision of parameter estimates, Akaike's Information Criterion, and Schwarz's Criterion. After the final model is developed, plasma CL, Vd, C max , T max , AUC, and t 1 / 2 Estimates of PK parameters are reported, including: Pulmonary uptake is expressed as the lung / plasma (L / P) concentration ratio.
[0246] Alternative approach: If phosphorylation site-specific antibodies are not available and phosphorylation does not cause a detectable shift on immunoblots, cell lysates can be enriched using TiO2 prior to immunoblotting. Incubation times can be adjusted, if necessary, based on the results of in vitro and in vivo proteomics and immunoblotting. Despite the use of maximal starting material, or isolated cell fractions, low protein abundance can prevent the detection of phosphorylated proteins in cell lysates. In this case, the use of LC-MS-MS can enhance the phosphoproteome analysis of cells in vivo and comprehensively analyze the effect of inhibitors on phosphorylated peptide patterns in an in vitro kinase assay of p38α using cell lysates as substrates after inactivating the endogenous kinase with 5'-4-fluorosulfonylbenzoyl adenosine (FSBA). If results without labeling are equivocal, stable isotope dimethyl labeling can be used. Other supporting techniques include hydrogen-deuterium exchange mass spectrometry and NMR, as well as DSF / STD-NMR to assess binding to wild-type p38α and CADD target mutants. Surface plasmon resonance (SPR) (Biacore T200 Core) can be evaluated as an alternative to ITC to reduce protein / compound requirements.
[0247] Statistical methods: Data are presented as mean ± SE. Differences between more than two groups were analyzed by applying Tukey's honestly significant difference test to one-way analysis of variance (ANOVA). Differences between dose-response curves were analyzed by multivariate ANOVA (MANOVA), with a p-value of less than 0.05 considered significant.
[0248] Example 1: CADD modeling of p38 MAPK substrate docking site, compound identification, and screening of compounds for direct, selective interaction with p38α The inhibitors and methods of the present invention involve a CADD-based strategy to identify low molecular weight compounds predicted to bind near the ED substrate docking site of mouse unphosphorylated p38α (MAPK14 variant-1; PDB: 1P38), which is >99% identical to human p38α (variant-2) (Figure 1 A The ED and CD sites of p38α are located at either end of the substrate-binding groove, on opposite sides of the protein's catalytic site (Figure 1). A We identified a pocket near the ED binding site that contains 10 amino acids, only 7 of which are identical in p38α and p38β (Fig. 1 B ). Structural superposition of the mouse unphosphorylated (PDB:1p38) and doubly phosphorylated p38α (PDB:3PY3) structures revealed that the targeting pockets of the two forms overlap almost perfectly (Figure 1). C ).
[0249] An overview of the CADD screening and compound testing protocol is shown in Figure 1 D Compounds from the Maybridge screening collection were analyzed for binding to the target p38α pocket based on van der Waals (VDW) and electrostatic interaction energies, chemical diversity by chemical fingerprint-based cluster analysis, solubility, molecular weight, and the number of hydrogen-bonding functionalities that maximize bioavailability.
[0250] From a panel of 150 diverse compounds selected for potential biological testing (Table 3), 20 structurally distinct compounds were selected for functional analysis (Table 2). [Table 4] [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4]
[0251] Test compounds at 10-100 μM were screened for binding to recombinant p38α and ERK2 using DSF (Figure 1 E , Table 1). Five compounds caused concentration-dependent stabilization of p38α and showed binding. Three of these also stabilized ERK2 (3, 5, and 141, highlighted in yellow (with a "*")), and two, namely, UM60 (N2,N7-di(2-hydroxyethyl)-9-oxo-9H-2,7-fluorenedisulfonamide) and UM101 (4-chloro-N-{4-[(1,1-dioxo-1lambda-6,4-thiazinane-4-yl)methyl]phenyl}benzamide), stabilized p38α but not ERK2 (highlighted in blue, with a "+")). These two structurally distinct compounds (Figure 1) F ) was added at 100 μM and increased the melting temperature of p38α by approximately 0.7°C, compared to the 6°C increase caused by SB203580.
[0252] MC SILCS docking into the ED site of UM101 and GFE FragMap analysis identified several structural features that could be modified to improve selectivity and potency (Figure 7). The modifiable sites on UM101 correspond to the sites identified in the NMR STD analysis to interact with p38α (Figure 3). F ~3 K ).
[0253] Example 2: Effect of compounds on endothelial barrier function The ability of UM60 and UM101 to stabilize the endothelial barrier to macromolecules and neutrophils in TNFα- and heat-challenged HMVECL monolayers was tested (Figure 2). A 6-hour exposure to a combination of 1 ng / ml TNFα and heat (39.5°C) increased permeability to 10 kDa dextran by 2.8-fold compared to untreated cells at 37°C. Pretreatment with 10 μM SB203580 for 30 min reduced TNFα / heat-induced permeability by 50% (Figure 2). A Pretreatment with 10 and 25 μM UM60 had no effect on permeability, but 100 μM UM60 reduced the TNFα / hyperthermia-induced increase in permeability by 71%, whereas 10, 25, and 100 μM UM101 reduced the TNFα / hyperthermia-induced increase in permeability by 74%, 89%, and >100%, respectively.
[0254] Preincubation of HMVECL for 6 h at 39.5°C resulted in a subsequent transendothelial migration (TEM) of IL-8-specific neutrophils of 22.8 ± 0.45 × 10 3 to 31.8±0.54×10 3 (neutrophil count) increased (Figure 2 B ). Pretreatment with 10 μM SB203580 reduced heat-enhanced neutrophil TEM by 84%. UM60 at 10 and 25 μM, and UM101 at 10 μM reduced the heat-enhanced increase in TEM by 18%, 89%, and 95%. UM60 at 50 μM, and UM101 at 25 and 50 μM reduced TEM below baseline levels. When added to HMVECLs at 100 μM for 48 h, neither compound was toxic in the LDH release and MTS assays.
[0255] Example 3: Comparison of the efficacy of SB203580 and UM101 in mouse ALI We compared the efficacy of UM60, UM101, and SB203580 in mitigating transalveolar protein and neutrophil extravasation in a mouse model of LPS / hyperthermia-induced ALI ( Figure 2 C and Figure 2 DMice received a single intraperitoneal injection of 100, 300, 500, or 1000 μg UM101, 1000 μg UM60, or 1000 μg SB203580 in 0.5 ml 2% DMSO 30 min prior to intratracheal instillation of 50 μg LPS and were transferred to a heat chamber. Control mice received DMSO. Four of six UM60-treated mice, one of six SB203580-treated mice, and one of eleven DMSO-treated control mice died within 24 h. All 16 UM101-pretreated mice survived. Lung lavage fluid from DMSO-pretreated, LPS / heat-challenged mice contained 1.09 ± 0.19 mg / ml protein and 3.97 ± 1.07 × 10 6 Compared to DMSO-treated controls, lavage protein concentration and neutrophil content in mice pretreated with 1000 μg SB203580 were reduced by 42% and 46.8%, respectively. Lavage protein concentration in mice pretreated with 100 μg, 300 μg, 500 μg, and 1000 μg UM101 was reduced by 0%, 44.1%, 43.9%, and 92.9%, respectively, and lavage neutrophil content was reduced by 44.4%, 49.5%, 55.3%, and 54%, respectively.
[0256] Example 4: Effects of SB203580 and UM101 on LPS-induced gene expression in human THP1 promonocytes The effects of UM101 and SB203580 on inflammatory cytokine expression were compared by pretreating PMA-differentiated THP1 cells with 25 μM SB203580 or 10, 25, or 100 μM UM101 for 30 min, stimulating them with 100 ng / ml LPS, and harvesting RNA 4 h later for analysis by PCR-based cytokine arrays. SB203580 inhibited the expression of 7 of the 16 LPS-stimulated genes in the array, namely IL-1α, IL-8, TNFSF8 (CD30 ligand), TNFSF9 (CD137 ligand), CXCL5, CCL7, and CCL17 (Table 4). UM101 inhibited the expression of all SB203580-inhibited genes except TNFSF9, and also inhibited the four SB203580-insensitive genes: IL-1β, CXCL1, TNFSF15, and CCL5. [Table 6]
[0257] Example 5: Comparison of the effects of SB203580 and UM101 on TNFα-induced gene expression in HMVECL We compared the effects of UM101 and SB203580 on TNFα-induced gene expression in HMVECL using RNASeq. HMVECL were pretreated with 10 μM SB203580 or 100 μM UM101 for 1 h, followed by stimulation with 10 ng / ml TNFα for 3 h. A UM101 concentration 10-fold higher than its biologically effective dose in the HMVECL barrier assay was used to ensure identification of any partial overlap with SB203580. The TNFα concentrations and stimulation durations used were based on previously published studies and confirmed by preliminary qRT-PCR analysis of IL-8 and IL-1β mRNA expression (Figure 4). After filtering the RNASeq results for genes with 10 or more reads in at least one sample per experiment, we found 511 genes that were upregulated by 2-fold or more and 520 genes that were downregulated by 2-fold or more by TNFα treatment (Table 5).
Table 7-1
Table 7-2
Table 7-3
Table 7-4
Table 7-5
Table 7-6
Table 7-7
Table 7-8
Table 7-9
Table 7-10
Table 7-11
Table 7-12
Table 7-13
Table 7-14
Table 7-15
Table 7-16
Table 7-17
Table 7-18
Table 7-19
Table 7-20
Table 7-21
Table 7-22
Table 7-23
[0258] SB203580 inhibited the expression of 61 TNFα-induced genes, 28 of which were also inhibited by UM101 (Table 6, Table 5, Figure 5). SB203580 increased the expression of 38 genes, 10 of which were also increased by UM101. Of the 28 genes inhibited by both SB203580 and UM101, 22 encoded known proteins and included IL-1β, CCL17, MMP9, IDO1, CXCL5, CXCL10, and CXCL11, hyaluronan synthase-3, MUC4, and PLA2 (Table 6). Of the 33 genes inhibited by SB203580 but not by UM101, 24 encoded known proteins and included GM-CSF, IL-1α, TNFα, IL-12 receptor-β1, and hyaluronan synthase-2 (Table 6). [Table 8-1] [Table 8-2]
[0259] The differentially expressed genes were further analyzed using PathwayNet and Ingenuity™ tools to identify transcription factors and biological pathways regulated by the two inhibitors. PathwayNet analysis suggested that UM101 inhibits some transcription factors inhibited by SB203580 (Stat-1, c-Fos, c-Jun, NFκB, p53, PPARγ, and Sp1), but not others (ATF1, ATF2, Elk1, c / EBPβ, USF1, SMAD3, FOXO1, and CREB via MSK1 / 2). Ingenuity™ analysis suggested that both SB203580 and UM101 inhibited dendritic cell maturation, triggering receptor expressed on myeloid cells-1 (TREM1), high mobility group box 1 (HMGB1), and NFκB pathways, and both increased liver X receptor / retinoid X receptor (LXR / RXR) activation, whereas only SB203580 inhibited IL-6, acute phase, and cholecystokinin / gastrin-mediated pathways ( Figure 3 A ) UM101 at 100 μM reduced expression of 115 genes and increased expression of 119 genes that were not modified by SB203580 (Table 5). Ingenuity™ pathway analysis suggested reduced Toll-like receptor and Wnt / β-catenin signaling, and increased nitric oxide in cardiovascular disease pathways (Figure 3). B ).
[0260] Example 6: Comparison of the effects of SB203580 and UM101 on p38 MAPK substrate phosphorylation profiles To assess whether UM101 selectively inhibits phosphorylation consistent with its targets, HeLa cells were pretreated with 10 μM SB203580, 50 μM UM101, or 0.1% DMSO (vehicle control) for 30 min and then treated with the p38 activator anisomycin (25 μg / ml), and phosphorylated MK2 and phosphorylated Stat-1 were analyzed by immunoblot ( Fig. 3 CAnisomycin-stimulated phosphorylation of MK2 and Stat-1 was reduced by both 10 μM SB203580 and 50 μM UM1010, but was more reduced by SB203580.
[0261] Example 7: Analysis of specific binding of UM101 to p38α DSF was used to analyze the concentration-specific binding of UM101 to p38α and p38β. SB203580 stabilized both p38α and p38β, whereas UM101 stabilized only p38α (Figure 3). D To confirm that UM101 bound to the CADD target pocket, we used DSF to compare the binding of UM101 and SB203580 to wild-type p38α and mutant p38α (in which 4 of the 10 target pocket amino acids were substituted, R49K / HL107-8TF / K165R) (Figure 3). E The mutant showed binding to SB203580, identical to wild-type p38α, but no binding to UM101.
[0262] Saturation transfer difference (STD)-NMR was used to confirm the selective binding of UM101 to the CADD target pocket of p38α. The 1D spectrum of UM101 in the presence of p38α is shown in Figure 3. F The STD spectrum of the same sample is shown in Fig. 3. G The peaks in the 1D spectrum are labeled according to the tentative peak assignments for UM101 in aqueous form, based on the 1D proton and C13 and 2D-HMBC experiment assignments for UM101 in 2 mM d6-DMSO. The shifts in the peaks in the STD spectrum correspond well with the shifts in the peaks in the 1D spectrum, thus indicating that protons in both aromatic rings of UM101 interact with p38α. In contrast, the 1D spectra of UM101 with p38β and mutant p38α were similar to the 1D spectra of UM101 / p38α (Figure 3), but H and Figure 3 J ), p38β (Fig. 3 I ) and mutant p38α (Fig. 3 KThe interaction of UM101 with p38β and mutant p38α is much weaker, as shown by barely discernible aromatic proton peaks in the STD spectrum of UM101 with p38β.
[0263] Example 8: Synthetic methods for preparing exemplary compounds of the present invention General Chemistry Methods: All air- or moisture-sensitive reactions were performed under a positive pressure of nitrogen using oven-dried glassware. Chemical reagents and anhydrous solvents were obtained from commercial sources and used as received.
[0264] The p38α MAPK inhibitor of the present invention can be prepared by methods generally known in the art. For example, compound UM101 can be prepared as shown in scheme 1. UM101 can be prepared in two steps from three commercially available fragments (scheme 1), which facilitates its optimization. Acylation of 4-aminobenzaldehyde with 4-chlorobenzoyl chloride in the presence of diisopropylamine (DIPEA) produces intermediate aldehyde. Subsequent reductive amination of the aldehyde with thiomorpholine 1,1-dioxide and sodium triacetoxyborohydride (NaBH(OAc)3) gives UM101. [ka]
[0265] A structure-activity relationship (SAR) focused on UM101 and additional lead compounds is performed to determine the information used to achieve its pharmacophore and its optimization, for example by feeding this information back into the CADD model to improve its predictability and thus facilitate subsequent design cycles. A summary of the proposed modifications to UM101 is shown in Scheme 2. This is driven by SILCS molecular modeling and addresses improved binding affinity and specificity, as well as enhanced physicochemical properties. Importantly, STD-NMR analysis of UM101 confirmed that both of its aromatic rings interact with proteins, and thus modifications of these rings will affect binding affinity. First, the positively charged (under physiological conditions) piperidine-type nitrogens of UM101 are retained in some embodiments, as they are predicted to interact with negatively charged residues such as D112 and D168. According to FragMaps, aliphatic (e.g., cyclohexyl) or aromatic (e.g., furan) substituents away from the central phenyl ring should enhance binding to proteins through interactions with V30, V38, A51, I84, L108, and L167. In addition, the presence of hydrogen bond acceptor maps overlapping with the aliphatic maps suggests that in some embodiments, a combined aliphatic / hydrogen bond acceptor group such as OEt is incorporated at the ortho position relative to the aniline nitrogen. Hydrogen bond donor groups (e.g., NH2, OH) and / or acceptor groups (e.g., OMe, isoxazole) can be incorporated at the ortho and meta positions of the peripheral chlorophenyl ring in some embodiments, and replace the chloropyridyl ring in other embodiments. These changes further increase the solubility of the compound. In some embodiments, the chlorine of the chlorophenyl ring interacts moderately with proteins as judged by SILCS GFE analysis, but this site is altered with alternative hydrophobic and more polar groups in other embodiments. The trans amide bond is modified in some embodiments to a rigid E-alkene and in other embodiments to a more flexible sulfonamide.Based on SILCS GFE analysis, the sulfone SO2 group contributes -0.5 kcal / mol to binding, indicating that in some embodiments, this region of the molecule may be utilized to optimize the physicochemical properties of the molecule without compromising binding affinity. For example, the SO2 group is replaced with a polar oxygen atom in some embodiments, and also with an NMe group in other embodiments. [ka]
[0266] Example 9: Novel non-ATP / catalytic site p38 mitogen-activated protein kinase inhibitors Using computer-aided drug design (CADD), novel small molecule compounds were identified that target selected substrate binding sites and inhibit p38 mitogen-activated protein (MAP) kinase activity that contributes to acute lung injury. These compounds are unique in that they are non-ATP / catalytic site kinase inhibitors, providing an alternative to current p38 MAP kinase inhibitors that target the ATP binding site or catalytic site and block all enzymatic activity. Compound UM101 targets the p38α MAP kinase isoform, which is the major p38 MAP kinase isoform involved in tissue damage associated with chronic inflammation and acute lung injury. Current p38 MAP kinase inhibitors target the ATP binding site or catalytic site, block all enzymatic activity, and lack isoform selectivity. In contrast, the compounds disclosed herein are unique in that their target site is directed against protein-substrate interactions and specifically blocks p38α MAP kinase function.
[0267] Novel UM101 analogs were synthesized (Schemes 3-5) and tested for interaction with p38α MAP kinase and biological activity. [ka] [ka] [ka]
[0268] Two lines of evidence suggest that the lead compound may improve lung barrier function and prevent lung injury. First, the compound can block thrombin-induced cell permeability in human vascular endothelial cells (Figure 8). Second, in mice challenged with LPS to induce lung inflammation, protein leakage into bronchoalveolar lavage fluid was reduced in the presence of parent compound UM101, as well as analogs SF-6-222 and SF-7-009 (Figure 9), or analogs SF-6-222, SF-7-009, and SF-7-044 (Figure 10). As shown in Figure 9, UM101 and analogs inhibit acute lung injury in a mouse model. Mice were pretreated with 1 mg of test compound (ip) and then treated with 100 mg of LPS (it) at 39°C to induce inflammation. Lung injury was assessed by measuring total protein in the lung lavage fluid. As shown in Figure 10, UM101 and analogs inhibit acute lung injury in a mouse model. All mice were administered 50 μg LPS (it) and kept at 39°C for 24 hours. All treatments were 1 mg in 0.5 ml DMSO and administered 6 hours after LPS. Mean ± SM, n = 5. *, p = 0.03 vs. DMSO #1, †, p = 0.16 vs. DMSO #2. Lung injury was assessed by measuring total protein in lung lavage fluid.
[0269] A useful application of the present invention is to provide new therapies for acute lung injury and other diseases caused by inflammation and endothelial permeability. Furthermore, the present invention aims to overcome problems with toxicity and poor efficacy with current p38 MAP kinase inhibitors used in the clinic to treat inflammation.
[0270] Several patent and non-patent publications are cited herein in order to describe the state of the art related to the present invention. The entire disclosure of each of these publications is incorporated herein by reference.
[0271] While specific embodiments of the present invention have been described and / or exemplified above, various other embodiments will be apparent to those skilled in the art from the foregoing disclosure. Thus, the present invention is not limited to the specific embodiments described and / or exemplified, but is capable of considerable variation and modification without departing from the scope and spirit of the appended claims.
[0272] Furthermore, as used herein, the term "about" means that amounts, sizes, formulations, parameters, shapes, and other quantities and characteristics need not be exact, but may be approximate and / or larger or smaller, as desired, to reflect tolerances, conversion factors, rounding, measurement errors, and the like, as well as other factors known to those of ordinary skill in the art. In general, an amount, size, formulation, parameter, shape, or other quantity or characteristic is "about" or "approximately" whether or not it is expressly stated as such.
[0273] In addition, the transitional terms "comprising," "consisting essentially of," and "consisting of," when used in the appended claims in their original and amended forms, define the claims in terms of what additional, unrecited claim elements or steps, if any, are excluded from the claim(s). The term "comprising" is intended to be inclusive or open-ended and does not exclude any additional, unrecited elements, methods, steps, or materials. The term "consisting of" excludes any elements, steps, or materials other than those specified in the claim, and in the latter case, excludes impurities ordinarily associated with the specified material(s). The term "consisting essentially of" limits the scope of the claim to certain elements, steps, or materials that do not materially affect the basic and novel characteristic(s) of the claimed invention. All compounds, compositions, formulations, and methods described herein that embody the present invention may, in alternative embodiments, be more specifically defined by any of the transition terms "comprising," "consisting essentially of," and "consisting of." References JPEG0007594787000078.jpg213155 JPEG0007594787000079.jpg214155 JPEG0007594787000080.jpg214155 JPEG0007594787000081.jpg215155 JPEG0007594787000082.jpg215155 JPEG0007594787000083.jpg214155 JPEG0007594787000084.jpg216155 JPEG0007594787000085.jpg215155 JPEG0007594787000086.jpg222155 JPEG0007594787000087.jpg222155 JPEG0007594787000088.jpg139155
Claims
1. A compound of formula I, or a pharma- ceutically acceptable salt thereof, 【Chemistry 1】 In formula I, L 1 But -CH 2 - and L 2 But -NHSO 2 - and R 3 , R 4 , R 5 , and R 6 each is hydrogen; Ar 1 is the formula: 【Chemistry 2】 In the formula, R 1a , and R 2a are independently halogen, C 1-10 Alkyl, substituted C 1-10 is alkyl, -NR 1 R 2 is a group represented by the following formula: 【Chemistry 3】 wherein R 7 is hydrogen, C 1-10 Alkyl and substituted C 1-10 alkyl; Ar 2 is 5-18 membered heteroaryl, or a pharma- ceutically acceptable salt thereof.
2. Each of the substituents is independently hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -SC(O)-R a , -N(R a ) 2 , -C(O)R a , -C(O)OR a , -C(O)SR a , -OC(O)N(R a ) 2 , -C(O)N(R a ) 2 , -N(R a ) C(O)OR a , -N(R a ) C(O)R a , -N(R a ) C(O)N(R a ) 2 , -N(R a ) C(NR a ) N (R a ) 2 , -N(R a ) S (O) t R a (t is 1 or 2), -S(O) t R a (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t N (R a ) 2 (t is 1 or 2), and PO 3 (R a ) 2 is selected from R a is independently selected at each occurrence from hydrogen, optionally substituted alkyl, optionally substituted fluoroalkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl, or a pharma- ceutically acceptable salt thereof.
3. R 1a , and R 2a Each of is independently a halogen, and C 1-3 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt thereof, wherein: R is selected from the group consisting of aryl, ... and aryl;
4. R 1a , and R 2a Each of the groups is independently 1-3 4. The compound of claim 3, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;
5. Ar 2 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein: is 5-membered heteroaryl.
6. 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof, wherein said 5-membered heteroaryl is selected from furan, thiophene, pyrrole, and imidazole.
7. The -NR of formula I 1 R 2 is a group represented by the following formula: 【Chemistry 4】 The compound according to any one of claims 1 to 6, selected from
8. The compound represented by formula (1087): 【Chemistry 5】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
9. The compound represented by formula (1085): 【Chemistry 6】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
10. The compound represented by formula (1086): 【Chemistry 7】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
11. The compound represented by formula (1088): 【Chemistry 8】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
12. The compound represented by formula (1089): 【Chemistry 9】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
13. The compound represented by formula (1090): 【Chemistry 10】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof.
15. 15. The pharmaceutical composition of claim 14 for the treatment of cancer in a patient.
16. 15. A pharmaceutical composition according to claim 14 for the treatment of an inflammatory disease in a patient.
17. 17. The pharmaceutical composition of claim 16, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), and acute lung injury (ALI).
18. 16. Use of a compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 14 or 15, in the manufacture of a medicament for the treatment of cancer.
19. Use of a compound according to any one of claims 1 to 13 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 14 or 16, in the manufacture of a medicament for the treatment of an inflammatory disease.
Citation Information
Patent Citations
NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF
WO2017223284A1
Cited By
NON-ATP / CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
JP2023106403A
